<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Perioperative medication management
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Perioperative medication management
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Perioperative medication management
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Visala Muluk, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Steven L Cohn, MD, MACP, SFHM, FRCP
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Christopher Whinney, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Andrew D Auerbach, MD, MPH
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Natalie F Holt, MD, MPH
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Jane Givens, MD, MSCE
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Nov 30, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         At least 50 percent of patients undergoing surgery take medications on a regular basis [
         <a href="#rid1">
          1
         </a>
         ]. Clinicians often must decide if chronic medications should be continued in the perioperative period. Unfortunately, there are few outcome data about the majority of medications taken in the perioperative period.
        </p>
        <p>
         This lack of medical evidence is reflected by the large variation in perioperative management recommendations [
         <a href="#rid2">
          2
         </a>
         ]. The recommendations in this review are to a large degree expert opinion, based on information from other reviews [
         <a href="#rid3">
          3,4
         </a>
         ] and textbooks, along with clinical experience and theoretic considerations.
        </p>
        <p>
         This topic will focus on medications known to have perioperative effects, those known to interact with anesthetic agents, and those in common use. An overview of preoperative patient assessment and details about perioperative management for specific medications are presented separately. (See
         <a class="medical medical_review" href="/z/d/html/4815.html" rel="external">
          "Overview of the principles of medical consultation and perioperative medicine"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3868.html" rel="external">
          "Perioperative management of hypertension"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1312.html" rel="external">
          "Perioperative management of patients receiving anticoagulants"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/146.html" rel="external">
          "The management of the surgical patient taking glucocorticoids"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2">
         <span class="h1">
          PRINCIPLES OF MEDICATION MANAGEMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         The following principles inform the management of chronic medications in the perioperative period:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A complete medication history should be obtained, and all clinicians involved in patient management (eg, surgeon, anesthesiologist, medical consultants) should review the medication history. Medication use reported by the patient should be verified (medication reconciliation) to address accuracy of drugs and doses [
         <a href="#rid5">
          5
         </a>
         ]. This should include all over-the-counter and herbal/complementary medications, as well as prescription drugs. In addition, substance use information (including alcohol, nicotine, and illicit drugs) should be elicited.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Medications associated with known medical morbidity if withdrawn abruptly should be continued in the perioperative period or tapered if feasible. Intravenous, transdermal, or transmucosal medicines should be substituted when absorption will be impaired because of loss of gastrointestinal function or restrictions on oral intake. Medications thought to increase the risk of anesthetic or surgical complications and not essential for the short-term should be held through the perioperative period [
         <a href="#rid3">
          3
         </a>
         ]. Other medications can be discontinued or continued based upon clinician judgment.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The many medications administered perioperatively during a relatively short period increase the potential for drug-drug interactions.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The metabolism and elimination of medications and their metabolites may be altered during the perioperative period. In particular, gastrointestinal absorption of oral medications may be impaired due to changes in splanchnic blood flow and edema [
         <a href="#rid6">
          6
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The majority of medications can be resumed once the patient is able to tolerate oral intake. The main exceptions to this are medications that impact the bleeding or thromboembolic risk and are discussed in detail in the relevant medication sections below.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3">
         <span class="h1">
          CARDIOVASCULAR MEDICATIONS
         </span>
         <span class="headingEndMark">
          —
         </span>
         For elective surgery, preoperative planning and care should be optimized to reduce risk and minimize the need for acute changes in medication management perioperatively  (
         <a class="graphic graphic_table graphicRef62659" href="/z/d/graphic/62659.html" rel="external">
          table 1
         </a>
         ). For example, we suggest control of clinical signs of heart failure (HF) for one week or longer preoperatively if time permits. (See
         <a class="medical medical_review" href="/z/d/html/105407.html" rel="external">
          "Perioperative management of heart failure in patients undergoing noncardiac surgery", section on 'Preoperative management'
         </a>
         .) Although the optimum intraoperative blood pressure target is unclear, episodes of either hypotension or hypertension should be avoided or promptly treated to minimize the potential for adverse cardiovascular and cerebrovascular outcomes [
         <a href="#rid7">
          7
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H4">
         <span class="h2">
          Beta blockers
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Benefit/risk
         </strong>
         – Beta blockers have a number of potential beneficial effects when taken perioperatively. Beta blockers reduce ischemia by decreasing myocardial oxygen demand due to increased catecholamine release. They may also help prevent or control arrhythmias. Patients who take beta blockers chronically for management of angina are at risk of ischemia with withdrawal of beta blockade. Acute withdrawal of a beta blocker pre- or postoperatively can lead to substantial morbidity and even mortality [
         <a href="#rid8">
          8-10
         </a>
         ]. Withdrawal issues are of less concern when beta blockers are used for hypertension or migraine prophylaxis.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Whether to initiate beta blockers as prophylaxis for ischemia in the perioperative period in patients at increased risk for coronary disease is complex and discussed separately [
         <a href="#rid11">
          11
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/6615.html" rel="external">
          "Management of cardiac risk for noncardiac surgery", section on 'Beta blockers'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Potential adverse effects of perioperative beta blockade include bradycardia and hypotension. Nonselective beta blockers can interact with epinephrine, used for infiltration anesthesia or management of intraoperative anaphylaxis [
         <a href="#rid12">
          12
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/6615.html" rel="external">
          "Management of cardiac risk for noncardiac surgery"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/967.html" rel="external">
          "Major side effects of beta blockers", section on 'Beta blocker withdrawal'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Continue/discontinue
         </strong>
         – In light of the potential benefits of perioperative beta blockade, minimal adverse effects, and consequences of acute withdrawal, we recommend that beta blockers be continued in the perioperative period and continued throughout the hospital stay. The dose of the beta blocker should be closely regulated throughout the perioperative period to maintain the blood pressure and heart rate (rate-pressure product) below the patient's ischemic threshold.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Since adequate beta blockade can take weeks to achieve safely in patients with systolic heart failure, we prefer initiation of beta blockade in the preoperative period only if acute decompensated heart failure is not present and surgery can be substantially delayed. If surgery is urgent, we prefer postponing beta blockade until a later date. (See
         <a class="medical medical_review" href="/z/d/html/105407.html" rel="external">
          "Perioperative management of heart failure in patients undergoing noncardiac surgery", section on 'Medication management'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Formulations/alternatives
         </strong>
         – Intravenous forms of beta blockade, such as
         <a class="drug drug_general" data-topicid="9645" href="/z/d/drug information/9645.html" rel="external">
          metoprolol
         </a>
         ,
         <a class="drug drug_general" data-topicid="9829" href="/z/d/drug information/9829.html" rel="external">
          propranolol
         </a>
         , and
         <a class="drug drug_general" data-topicid="9540" href="/z/d/drug information/9540.html" rel="external">
          labetalol
         </a>
         , should be given if the patient cannot take oral medications [
         <a href="#rid13">
          13,14
         </a>
         ].
         <a class="drug drug_general" data-topicid="9420" href="/z/d/drug information/9420.html" rel="external">
          Esmolol
         </a>
         is also available to be used intraoperatively or in an intensive care unit (ICU) but cannot be administered on a regular hospital floor. We have a slight preference for beta 1 cardioselective beta blockers, since they are less likely to cause adverse pulmonary and peripheral vascular effects and may be associated with a lower risk of postoperative stroke. Several studies suggest that the risk of perioperative stroke may vary with the specific beta blocker used, and that metoprolol, compared with
         <a class="drug drug_general" data-topicid="8940" href="/z/d/drug information/8940.html" rel="external">
          atenolol
         </a>
         , has been associated with a greater risk of perioperative stroke [
         <a href="#rid15">
          15-19
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         However, patients who are taking a nonselective beta blocker (eg,
         <a class="drug drug_general" data-topicid="9829" href="/z/d/drug information/9829.html" rel="external">
          propranolol
         </a>
         ) chronically do not need to be switched to a beta 1 selective agent perioperatively.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H5">
         <span class="h2">
          Alpha 2 agonists
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Benefit/risk
         </strong>
         – Although earlier smaller randomized trials suggested that centrally acting sympatholytic drugs such as
         <a class="drug drug_general" data-topicid="9285" href="/z/d/drug information/9285.html" rel="external">
          clonidine
         </a>
         may improve perioperative outcomes [
         <a href="#rid20">
          20-22
         </a>
         ], the larger POISE-2 randomized trial in 10,010 patients undergoing noncardiac surgery found that preoperative initiation of low-dose clonidine resulted in increased harm (no change in mortality or myocardial infarction but increase in clinically significant hypotension and nonfatal cardiac arrest) [
         <a href="#rid23">
          23
         </a>
         ]. A substudy of the trial also found no benefit of perioperatively administered clonidine in reducing the risk of acute kidney injury [
         <a href="#rid24">
          24
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         For patients already taking
         <a class="drug drug_general" data-topicid="9285" href="/z/d/drug information/9285.html" rel="external">
          clonidine
         </a>
         , abrupt withdrawal of clonidine can precipitate rebound hypertension [
         <a href="#rid25">
          25-27
         </a>
         ]. This usually occurs after abrupt cessation of fairly large oral doses (eg, greater than 0.8 mg/day) but has also been noted in patients using transdermal clonidine [
         <a href="#rid28">
          28
         </a>
         ]. Withdrawal symptoms have also been reported with
         <a class="drug drug_general" data-topicid="9635" href="/z/d/drug information/9635.html" rel="external">
          methyldopa
         </a>
         and
         <a class="drug drug_general" data-topicid="8510" href="/z/d/drug information/8510.html" rel="external">
          guanfacine
         </a>
         but are less likely because of their slower onset of action [
         <a href="#rid28">
          28
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/3864.html" rel="external">
          "Tapering and discontinuing antihypertensive medications"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Continue/discontinue
         </strong>
         – Given the possible negative consequences of withdrawal, we recommend that alpha 2 agonist drugs be continued in the perioperative period, but not initiated.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Formulations/alternatives
         </strong>
         – Transdermal
         <a class="drug drug_general" data-topicid="9285" href="/z/d/drug information/9285.html" rel="external">
          clonidine
         </a>
         is available for patients who likely will not be able to resume oral medications by 12 hours after surgery. The decision to substitute this form of therapy must be made before surgery; an equivalent dose of the transdermal preparation should be started three days prior to surgery while the oral clonidine is tapered. The persistent effect of transdermal clonidine for 24 to 48 hours after patch removal should be considered when transitioning back to the oral form.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Other centrally acting sympatholytic agents (eg,
         <a class="drug drug_general" data-topicid="9635" href="/z/d/drug information/9635.html" rel="external">
          methyldopa
         </a>
         or guanabenz) are rarely used today. Withdrawal from abrupt discontinuation has been reported but is less common because of their slower onset of action [
         <a href="#rid29">
          29,30
         </a>
         ]. For patients unable to take oral medications perioperatively, we recommend withholding methyldopa and guanabenz and using other parenteral hypertensive agents if hypertension becomes a problem [
         <a href="#rid25">
          25
         </a>
         ]. An intravenous form of methyldopa is available in the rare cases in which abrupt stoppage appears to be leading to a withdrawal syndrome.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H6">
         <span class="h2">
          Calcium channel blockers
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Benefit/risk
         </strong>
         – Data are limited regarding the risks and benefits of calcium channel blockers in the perioperative setting. Small trials have shown a more stable intraoperative hemodynamic profile in patients treated with continuous
         <a class="drug drug_general" data-topicid="9365" href="/z/d/drug information/9365.html" rel="external">
          diltiazem
         </a>
         , compared with placebo, during coronary bypass surgery [
         <a href="#rid31">
          31
         </a>
         ], but these studies are not large enough to demonstrate improved outcomes. In an observational study, continued use of calcium channel blockers was associated with reduced mortality for patients undergoing cardiac surgery [
         <a href="#rid32">
          32
         </a>
         ]. A meta-analysis found that use of calcium channel blockers was associated with reduced ischemia and atrial arrhythmia in patients undergoing noncardiac surgery [
         <a href="#rid33">
          33
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         There are no serious interactions between calcium channel blockers and anesthetic agents [
         <a href="#rid34">
          34
         </a>
         ]. A withdrawal syndrome is not typical of calcium channel blockers, although abrupt discontinuation of these drugs has been reported to cause severe vasospasm in patients undergoing coronary revascularization [
         <a href="#rid35">
          35
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Concerns have been raised about a possible association between calcium channel blockers and an increased risk of bleeding [
         <a href="#rid36">
          36
         </a>
         ]. A randomized trial in valvular surgery patients found that, compared with placebo, patients receiving
         <a class="drug drug_general" data-topicid="9702" href="/z/d/drug information/9702.html" rel="external">
          nimodipine
         </a>
         had increased bleeding [
         <a href="#rid37">
          37,38
         </a>
         ]. Reports conflict on whether there is a greater incidence of anemia in patients receiving calcium channel blockers after hip surgery [
         <a href="#rid39">
          39,40
         </a>
         ]. Two large trials in cardiac surgery patients did not find any association between bleeding risk and use of calcium channel blockers [
         <a href="#rid41">
          41
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Continue/discontinue
         </strong>
         – Despite little data regarding calcium channel blockers during the perioperative period, these agents appear safe and have theoretic benefit [
         <a href="#rid42">
          42
         </a>
         ]; data regarding bleeding risk are contradictory. Thus, we recommend that calcium channel blockers be continued in patients who are already taking them preoperatively [
         <a href="#rid42">
          42
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Formulations/alternatives
         </strong>
         – Intravenous
         <a class="drug drug_general" data-topicid="9365" href="/z/d/drug information/9365.html" rel="external">
          diltiazem
         </a>
         is available for patients who are unable to tolerate oral agents.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Most oral calcium channel blockers are formulated as extended release and should not be crushed for administration in enteral tubes. Short-acting calcium channel blockers are available (
         <a class="drug drug_general" data-topicid="9365" href="/z/d/drug information/9365.html" rel="external">
          diltiazem
         </a>
         ,
         <a class="drug drug_general" data-topicid="10043" href="/z/d/drug information/10043.html" rel="external">
          verapamil
         </a>
         ) and can be substituted with appropriate dosing interval adjustments. Short-acting
         <a class="drug drug_general" data-topicid="9700" href="/z/d/drug information/9700.html" rel="external">
          nifedipine
         </a>
         should be avoided, however, because it can cause rapid decreases in blood pressure.
         <a class="drug drug_general" data-topicid="8627" href="/z/d/drug information/8627.html" rel="external">
          Amlodipine
         </a>
         has a long washout period, and short-acting substitutes may not be necessary.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H7">
         <span class="h2">
          ACE inhibitors and angiotensin II receptor blockers
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Benefit/risk
         </strong>
         – The management of patients taking angiotensin-converting enzyme (ACE) inhibitors and angiotensin II receptor blockers (ARBs) preoperatively is controversial. ACE inhibitors and ARBs can theoretically blunt the compensatory activation of the renin-angiotensin system during surgery and result in prolonged hypotension. Also, the effect of these drugs may be different in noncardiac and cardiac surgery as well as with general and neuraxial anesthesia.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Data regarding use of ACE inhibitors and ARBs in the perioperative period are inconsistent, with many studies indicating some increased risk for peri- and postoperative hypotensive episodes but variable adverse effect on cardiovascular outcomes or respiratory outcomes when the medications are continued. Representative studies of outcomes involving noncardiac surgery include the following [
         <a href="#rid43">
          43-47
         </a>
         ]:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         In a randomized controlled trial of 275 patients on ACE inhibitors undergoing noncardiac (mainly orthopedic and spine) surgery, those who omitted their last preoperative ACE inhibitor dose were compared with those who continued the medication uninterrupted [
         <a href="#rid45">
          45
         </a>
         ]. Intraoperative and postoperative hypotension occurred less frequently in the group who omitted the last dose, but postoperative hypertensive events were more frequent (RR 1.95, 95% CI 1.14 to 3.34).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         In an observational cohort study of almost 15,000 patients (with 4802 taking either ACE inhibitors or ARBs for unspecified indications), withholding the ACE inhibitor/ARB 24 hours before noncardiac surgery was associated with a reduction in composite 30-day all-cause death, stroke, or myocardial injury (adjusted relative risk [ARR] 0.82, 95% CI 0.70-0.96) and intraoperative hypotension (ARR 0.80, 95% CI 0.72-0.93) [
         <a href="#rid47">
          47
         </a>
         ]. Withholding perioperative ACE inhibitor/ARB was not associated with risk of myocardial infarction or postoperative hypotension.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         In an observational study of over 12,000 patients on chronic diuretic therapy undergoing noncardiac surgery, ACE inhibitor/ARB treatment was associated with more frequent episodes of hypotension [
         <a href="#rid43">
          43
         </a>
         ]. However, there were no differences in the rates of postoperative myocardial infarction or renal failure between the two groups.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         In a propensity match study of 18,000 patients undergoing noncardiac surgery, no association was found between continued use of ACE inhibitors and intraoperative or postoperative upper-airway complications [
         <a href="#rid44">
          44
         </a>
         ]. Furthermore, uninterrupted perioperative ACE inhibitor use was not associated with in-hospital complications or increased 30-day mortality.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         In a meta-analysis including nine studies and over 6000 patients taking ACE inhibitors or ARBs undergoing noncardiac surgery, withholding these medications preoperatively was associated with significantly less intraoperative hypotension (odds ratio [OR] 0.63; 95% CI 0.47-0.85). There was, however, no difference in mortality (OR 0.97; 95% CI 0.62-1.52) or in the occurrence of major cardiovascular events (OR 1.12; 95% CI 0.82-1.52) [
         <a href="#rid46">
          46
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         In the SPACE trial, 262 patients aged ≥60 years undergoing elective noncardiac surgery were randomly assigned to either continue or discontinue renin-angiotensin (RAS) inhibitors prescribed for existing medical conditions. Patients who continued had lower rates of myocardial injury compared with those who discontinued (41.3 versus 48.3 percent, OR 0.77, 95% CI 0.45-1.31), fewer hypertensive adverse events (5.3 versus 12.4 percent, OR 0.4; 95% CI 0.16-1.00), and similar rates of hypotension (8.4 versus 9.3 percent) [
         <a href="#rid48">
          48
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Additional studies have evaluated the effect of ACE inhibitor therapy in patients undergoing coronary artery bypass graft (CABG) surgery:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         A trial randomly assigned 40 patients with good left ventricular function who were undergoing CABG surgery to continue or omit ACE inhibitors before surgery [
         <a href="#rid49">
          49
         </a>
         ]. Patients who omitted their ACE inhibitors required less vasopressors during surgery but required more vasodilators to control hypertension in the early postoperative period.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         A randomized trial of 47 patients on
         <a class="drug drug_general" data-topicid="9851" href="/z/d/drug information/9851.html" rel="external">
          ramipril
         </a>
         undergoing CABG on cardiopulmonary bypass (CPB) found that ACE inhibitor therapy predisposed to hypotension upon induction and in the post-CPB period, but prophylactic low-dose
         <a class="drug drug_general" data-topicid="10039" href="/z/d/drug information/10039.html" rel="external">
          vasopressin
         </a>
         infusion prevented post-CPB hypotension [
         <a href="#rid50">
          50
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Nonrandomized studies suggest a possible myocardial protective effect of ACE inhibitors in patients undergoing CABG surgery [
         <a href="#rid51">
          51,52
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Reports conflict on the effect of ACE inhibitors on the risk of acute kidney injury (AKI) [
         <a href="#rid53">
          53-57
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Continue/discontinue
         </strong>
         – We individualize the decision to continue or discontinue ACE inhibitors based on the indications for the drug, the patient's blood pressure, and the type of surgery and anesthesia planned. For most patients, we usually withhold them on the morning of surgery. However, when the indication is for heart failure or poorly controlled hypertension, we continue them to avoid further exacerbation of these conditions. Many anesthesiologists may prefer to withhold these medications on the morning of surgery based on concerns about possible hypotension, and in such cases when we favor continuation, we inform the anesthesiologist of our justification.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         We recommend resuming these agents as soon as possible postoperatively, as failure to restart ARBs within 48 hours after surgery has been associated with increased 30-day mortality (see
         <a class="medical medical_review" href="/z/d/html/105407.html" rel="external">
          "Perioperative management of heart failure in patients undergoing noncardiac surgery", section on 'Medication management'
         </a>
         ). A number of organizations have issued guidelines regarding the perioperative use of ACE inhibitors and ARBs [
         <a href="#rid58">
          58-62
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         As above, most findings suggest that continuing ACE inhibitors up to the time of surgery increases perioperative hypotension but possibly reduces the incidence of postoperative hypertension.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Formulations/alternatives
         </strong>
         –
         <a class="drug drug_general" data-topicid="9405" href="/z/d/drug information/9405.html" rel="external">
          Enalapril
         </a>
         is available for short-term intermittent intravenous administration, although it is used infrequently.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H8">
         <span class="h2">
          Diuretics
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Benefit/risk
         </strong>
         – The two major physiologic effects of concern of loop and thiazide-type diuretics are hypokalemia and hypovolemia.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Hypokalemia can theoretically increase the risk of perioperative arrhythmia, although observational studies of patients with structural heart disease have failed to find such a relationship [
         <a href="#rid63">
          63,64
         </a>
         ]. Additionally, hypokalemia might potentiate the effects of muscle relaxants used during anesthesia, as well as provoke paralytic ileus.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Systemic vasodilatation induced by anesthetic agents may cause hypotension in patients who are intravascularly depleted from diuretics. However, in a study of elective, noncardiac surgeries in patients chronically treated with
         <a class="drug drug_general" data-topicid="8482" href="/z/d/drug information/8482.html" rel="external">
          furosemide
         </a>
         , the administration of furosemide on the day of surgery did not significantly increase the risk for intraoperative hypotension [
         <a href="#rid65">
          65
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Continue/discontinue
         </strong>
         – There is no consensus on whether diuretics should be discontinued prior to elective surgery [
         <a href="#rid2">
          2
         </a>
         ]. Our approach depends upon the reason for diuretic use and on an individual patient's history.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         We advise patients who are taking diuretics for hypertension to hold the medication on the morning of surgery. Diuretics may theoretically increase the risk of intraoperative hypotension, and although unlikely to occur in patients on chronic therapy, it is reasonable to hold the medication for this reason.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         For patients receiving diuretic therapy to treat heart failure, diuretic continuation is based upon assessment of volume status, which should be evaluated and optimized preoperatively whenever possible. For patients with well-controlled heart failure and stable volume status, we generally recommend holding the morning dose of diuretic on the day of surgery. For patients with heart failure in whom fluid balance has historically been more difficult to control, we recommend continuing the diuretic without interruption.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         If diuretics are held the morning of surgery and volume overload develops, a quick diuresis can be initiated by intravenous administration perioperatively. (See
         <a class="medical medical_review" href="/z/d/html/105407.html" rel="external">
          "Perioperative management of heart failure in patients undergoing noncardiac surgery", section on 'Medication management'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         For patients who require perioperative diuretics, clinicians should pay close attention to potassium replacement.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Formulations/alternatives
         </strong>
         – Intravenous preparations of loop diuretics are available.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H9">
         <span class="h2">
          Non-statin hypolipidemic agents
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Benefit/risk
         </strong>
         –
         <a class="drug drug_general" data-topicid="9695" href="/z/d/drug information/9695.html" rel="external">
          Niacin
         </a>
         and fibric acid derivatives (
         <a class="drug drug_general" data-topicid="8488" href="/z/d/drug information/8488.html" rel="external">
          gemfibrozil
         </a>
         ,
         <a class="drug drug_general" data-topicid="91482" href="/z/d/drug information/91482.html" rel="external">
          fenofibrate
         </a>
         ) cause myopathy and rhabdomyolysis. The risk is higher when these agents are used in combination with statins, and surgery may also increase the risk of myopathy [
         <a href="#rid66">
          66-70
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/6833.html" rel="external">
          "Statin muscle-related adverse events"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Lipid-lowering agents that are bile sequestrants (
         <a class="drug drug_general" data-topicid="9258" href="/z/d/drug information/9258.html" rel="external">
          cholestyramine
         </a>
         and
         <a class="drug drug_general" data-topicid="9294" href="/z/d/drug information/9294.html" rel="external">
          colestipol
         </a>
         ) interfere with bowel absorption of multiple medications that may be required perioperatively.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The benefits or risks of
         <a class="drug drug_general" data-topicid="8790" href="/z/d/drug information/8790.html" rel="external">
          ezetimibe
         </a>
         in the perioperative period are unknown.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Continue/discontinue
         </strong>
         – We recommend temporary discontinuation of
         <a class="drug drug_general" data-topicid="9695" href="/z/d/drug information/9695.html" rel="external">
          niacin
         </a>
         , fibric acid derivatives, bile sequestrants, and
         <a class="drug drug_general" data-topicid="8790" href="/z/d/drug information/8790.html" rel="external">
          ezetimibe
         </a>
         perioperatively. Discontinuation is likely to be safe since these agents are given for the goal of long-term reduction in vascular morbidity [
         <a href="#rid67">
          67
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The optimal interval to discontinue these agents before surgery is unknown; we recommend they be stopped the day before surgery to allow for drug elimination.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H274987785">
         <span class="h2">
          Digoxin
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Benefit/risk
         </strong>
         – Studies on
         <a class="drug drug_general" data-topicid="9360" href="/z/d/drug information/9360.html" rel="external">
          digoxin
         </a>
         in the perioperative period are limited. The two indications for digoxin are to prevent hospitalization and readmission in patients with reduced left ventricular function and to control ventricular response in atrial fibrillation. One study found perioperative use of digoxin to be a predictor of postoperative ischemia, but this was probably because it was a marker of underlying cardiac disease [
         <a href="#rid71">
          71
         </a>
         ]. A subgroup analysis of patients undergoing intrathoracic surgery found that digoxin decreased the incidence of postoperative supraventricular arrhythmias [
         <a href="#rid72">
          72
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Continue/discontinue
         </strong>
         – We recommend continuing
         <a class="drug drug_general" data-topicid="9360" href="/z/d/drug information/9360.html" rel="external">
          digoxin
         </a>
         perioperatively. Obtaining a drug level preoperatively is not usually required.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Formulations/alternatives
         </strong>
         – Intravenous
         <a class="drug drug_general" data-topicid="9360" href="/z/d/drug information/9360.html" rel="external">
          digoxin
         </a>
         is available if needed.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H10">
         <span class="h2">
          Statins
         </span>
         <span class="headingEndMark">
          —
         </span>
         Evidence has become convincing that HMG CoA reductase inhibitors (statins) may prevent vascular events in the perioperative period. We recommend continuing statins throughout the perioperative period. This is discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/6615.html" rel="external">
          "Management of cardiac risk for noncardiac surgery", section on 'Statins'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H11">
         <span class="h1">
          GASTROINTESTINAL AGENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Recommendations for perioperative management of these agents are summarized in the table  (
         <a class="graphic graphic_table graphicRef56778" href="/z/d/graphic/56778.html" rel="external">
          table 2
         </a>
         ).
        </p>
        <p class="headingAnchor" id="H26237687">
         <span class="h2">
          H2 blockers and proton pump inhibitors
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Benefit/risk
         </strong>
         – There are several potential advantages of continuing H2 blockers or proton pump inhibitors perioperatively. The stress of surgery and other conditions (eg, intensive care unit [ICU] stay and mechanical ventilation) can increase the risk of stress-related mucosal damage, which may be minimized by administration of these drugs. (See
         <a class="medical medical_review" href="/z/d/html/1611.html" rel="external">
          "Stress ulcers in the intensive care unit: Diagnosis, management, and prevention"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In addition, gastric aspiration during anesthesia, though rare, can lead to severe pulmonary injury. Both H2 blockers and proton pump inhibitors decrease gastric volume and raise gastric fluid pH, thereby reducing the risk of chemical pneumonitis from aspiration [
         <a href="#rid73">
          73,74
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/7024.html" rel="external">
          "Aspiration pneumonia in adults", section on 'Chemical pneumonitis'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Although H2 blocker therapy is generally safe, rare central nervous system (CNS) reactions including confusion and delirium are associated with the use of intravenous H2 blockers in critically ill postoperative patients [
         <a href="#rid75">
          75
         </a>
         ]. Patient risk factors for CNS reactions include advanced age, organ dysfunction, and preexisting cognitive impairment. It is uncertain whether any H2 blocker is less likely to cause CNS effects than others. (See
         <a class="medical medical_review" href="/z/d/html/32.html" rel="external">
          "Antiulcer medications: Mechanism of action, pharmacology, and side effects", section on 'Adverse effects'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         An increased risk of
         <em>
          Clostridioides difficile
         </em>
         infection has been associated with proton pump inhibitor use. (See
         <a class="medical medical_review" href="/z/d/html/2696.html" rel="external">
          "
          <i>
           Clostridioides difficile
          </i>
          infection in adults: Epidemiology, microbiology, and pathophysiology"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2696.html" rel="external">
          "
          <i>
           Clostridioides difficile
          </i>
          infection in adults: Epidemiology, microbiology, and pathophysiology", section on 'Gastric acid suppression'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Neither H2 blockers nor proton pump inhibitors have been shown to interact with common anesthetic agents, although
         <a class="drug drug_general" data-topicid="9265" href="/z/d/drug information/9265.html" rel="external">
          cimetidine
         </a>
         can alter the metabolism of several drugs.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Continue/discontinue
         </strong>
         – Based upon the potential benefits and lack of contraindications, we recommend that patients who are taking either H2 blockers or proton pump inhibitors remain on these medications in the perioperative period.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Formulations/alternatives
         </strong>
         – Patients who are unable to take oral medications for a prolonged period should be switched to an intravenous form of H2 blocker or proton pump inhibitor  (
         <a class="graphic graphic_table graphicRef56778" href="/z/d/graphic/56778.html" rel="external">
          table 2
         </a>
         ). Intravenous H2 blockers are less costly.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H12">
         <span class="h1">
          PULMONARY AGENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Recommendations for perioperative management of these agents are summarized in the table  (
         <a class="graphic graphic_table graphicRef56778" href="/z/d/graphic/56778.html" rel="external">
          table 2
         </a>
         ).
        </p>
        <p class="headingAnchor" id="H13">
         <span class="h2">
          Inhaled beta agonists and anticholinergics
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Benefit/risk
         </strong>
         – Inhaled medications used to control obstructive pulmonary disease, such as beta agonists (
         <a class="drug drug_general" data-topicid="9396" href="/z/d/drug information/9396.html" rel="external">
          albuterol
         </a>
         ,
         <a class="drug drug_general" data-topicid="9875" href="/z/d/drug information/9875.html" rel="external">
          salmeterol
         </a>
         ,
         <a class="drug drug_general" data-topicid="8946" href="/z/d/drug information/8946.html" rel="external">
          formoterol
         </a>
         ) and anticholinergics (
         <a class="drug drug_general" data-topicid="8570" href="/z/d/drug information/8570.html" rel="external">
          ipratropium
         </a>
         ,
         <a class="drug drug_general" data-topicid="10300" href="/z/d/drug information/10300.html" rel="external">
          tiotropium
         </a>
         ), have been found to reduce the incidence of postoperative pulmonary complications in patients with asthma and chronic obstructive pulmonary disease and should be continued perioperatively. (See
         <a class="medical medical_review" href="/z/d/html/6970.html" rel="external">
          "Strategies to reduce postoperative pulmonary complications in adults"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Continue/discontinue
         </strong>
         – We recommend continuing beta agonists in the perioperative period, including the day of surgery.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Formulations/alternatives
         </strong>
         – Inhaled beta agonists and anticholinergics are normally administered on the morning of surgery. The drugs can be administered through a nebulizer or in the circuit of the ventilator when use of metered-dose inhalers is not possible.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H14">
         <span class="h2">
          Theophylline
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Benefit/risk
         </strong>
         – There are no data indicating whether continuation of
         <a class="drug drug_general" data-topicid="10281" href="/z/d/drug information/10281.html" rel="external">
          theophylline
         </a>
         in the perioperative period decreases pulmonary complications. Theophylline has the potential to cause serious arrhythmias and neurotoxicity at a level just beyond the therapeutic range, and theophylline metabolism is affected by many common perioperative medications.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Continue/discontinue
         </strong>
         – We recommend
         <a class="drug drug_general" data-topicid="10281" href="/z/d/drug information/10281.html" rel="external">
          theophylline
         </a>
         medications be discontinued the evening before surgery.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Formulations/alternatives
         </strong>
         – Other medications for treatment of obstructive lung disease can be initiated or adjusted, including inhaled beta agonists, glucocorticoids, and anticholinergic medications. (See
         <a class="medical medical_review" href="/z/d/html/6970.html" rel="external">
          "Strategies to reduce postoperative pulmonary complications in adults"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H15">
         <span class="h2">
          Glucocorticoids
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Benefit/risk
         </strong>
         – Patients with pulmonary disease who are maintained on glucocorticoids (corticosteroids) are at risk of adrenal insufficiency if steroids are abruptly withdrawn, particularly in the face of increased stress related to surgery. Additionally, glucocorticoids in such patients may be necessary to maintain optimal lung functions. The risk of possible perioperative complications related to glucocorticoids, including wound infections, is low [
         <a href="#rid76">
          76
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Continue/discontinue
         </strong>
         – Both inhaled and systemic glucocorticoids should be continued during the perioperative period. Issues related to preoperative stress dosing are discussed below. (See
         <a class="local">
          'Glucocorticoids'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H16">
         <span class="h2">
          Leukotriene inhibitors
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Benefit/risk
         </strong>
         – The leukotriene inhibitors
         <a class="drug drug_general" data-topicid="10052" href="/z/d/drug information/10052.html" rel="external">
          zafirlukast
         </a>
         and
         <a class="drug drug_general" data-topicid="9539" href="/z/d/drug information/9539.html" rel="external">
          montelukast
         </a>
         help maintain asthma control but are not used for acute therapy. (See
         <a class="medical medical_review" href="/z/d/html/553.html" rel="external">
          "Antileukotriene agents in the management of asthma"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The elimination half-life of these agents is relatively short, but their effect on asthma symptoms and pulmonary function continues for up to three weeks after cessation of treatment [
         <a href="#rid77">
          77
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         There is no evidence of a withdrawal syndrome with abrupt stoppage of these agents. We are aware of no evidence of harmful interactions of these drugs with anesthetics.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Continue/discontinue
         </strong>
         – We recommend that leukotriene inhibitors be given on the morning of surgery and resumed when the patient is tolerating oral medications.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Formulations/alternatives
         </strong>
         – No parenteral substitution is available or necessary given the long duration of action for leukotriene inhibitors.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H17">
         <span class="h1">
          ENDOCRINE AGENTS
         </span>
        </p>
        <p class="headingAnchor" id="H18">
         <span class="h2">
          Glucocorticoids
         </span>
         <span class="headingEndMark">
          —
         </span>
         The management of patients taking glucocorticoids preoperatively is discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/146.html" rel="external">
          "The management of the surgical patient taking glucocorticoids"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1826.html" rel="external">
          "Preoperative evaluation and perioperative management of patients with rheumatic diseases", section on 'Medication management'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H19">
         <span class="h2">
          Oral diabetic agents and insulin
         </span>
         <span class="headingEndMark">
          —
         </span>
         The management of diabetes mellitus, including management of oral agents and insulin in the perioperative period, is discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/1753.html" rel="external">
          "Perioperative management of blood glucose in adults with diabetes mellitus"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1766954240">
         <span class="h2">
          GLP-1 receptor agonists
         </span>
         <span class="headingEndMark">
          —
         </span>
         Delayed gastric emptying is a potential side effect of GLP-1 receptor antagonists (eg,
         <a class="drug drug_general" data-topicid="115980" href="/z/d/drug information/115980.html" rel="external">
          semaglutide
         </a>
         ,
         <a class="drug drug_general" data-topicid="9522" href="/z/d/drug information/9522.html" rel="external">
          liraglutide
         </a>
         ) which are used to treat diabetes and weight loss. For patients on daily dosing consider holding GLP-1 agonists on the day of the procedure/surgery. For patients on weekly dosing consider holding GLP-1 agonists a week prior to the procedure/surgery. Consider consulting an endocrinologist for bridging the antidiabetic therapy to avoid hyperglycemia [
         <a href="#rid78">
          78
         </a>
         ]. This is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/94214.html" rel="external">
          "Rapid sequence induction and intubation (RSII) for anesthesia", section on 'Patients taking GLP-1 receptor agonists'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3631798122">
         <span class="h2">
          Sodium-glucose cotransporter 2 inhibitors
         </span>
         <span class="headingEndMark">
          —
         </span>
         There have been reports of postoperative euglycemic diabetic ketoacidosis in patients with type 2 diabetes taking SGLT2 inhibitors (eg,
         <a class="drug drug_general" data-topicid="96484" href="/z/d/drug information/96484.html" rel="external">
          empagliflozin
         </a>
         ,
         <a class="drug drug_general" data-topicid="93383" href="/z/d/drug information/93383.html" rel="external">
          dapagliflozin
         </a>
         ,
         <a class="drug drug_general" data-topicid="88901" href="/z/d/drug information/88901.html" rel="external">
          canagliflozin
         </a>
         ,
         <a class="drug drug_general" data-topicid="116180" href="/z/d/drug information/116180.html" rel="external">
          ertugliflozin
         </a>
         ,
         <a class="drug drug_general" data-topicid="140647" href="/z/d/drug information/140647.html" rel="external">
          bexagliflozin
         </a>
         ). These agents should be stopped three to four days before surgery. (See
         <a class="medical medical_review" href="/z/d/html/109245.html" rel="external">
          "Sodium-glucose cotransporter 2 inhibitors for the treatment of hyperglycemia in type 2 diabetes mellitus", section on 'Adverse effects'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H20">
         <span class="h2">
          Oral contraceptives
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Benefit/risk
         </strong>
         – Oral contraceptives (OCs) are statistically the most frequent cause of thrombosis in young women due to their widespread use. The risk of thrombosis increases within four months of initiation and decreases to previous levels within three months of stopping treatment. Surgery itself is a risk factor for thrombosis and compounds the risk associated with oral contraceptive use.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         OCs with higher estrogen content (≥35 mcg) have a greater risk of thromboembolism compared with those with lower estrogen content (≤30 mcg). Nevertheless, even the lower estrogen content pills are associated with an increased risk of thrombosis [
         <a href="#rid79">
          79,80
         </a>
         ]. Estrogen/progestin patches also increase thrombosis risk. Risk also varies with type of progestin. (See
         <a class="medical medical_review" href="/z/d/html/7399.html" rel="external">
          "Combined estrogen-progestin contraception: Side effects and health concerns", section on 'Cardiovascular effects'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Continue/discontinue
         </strong>
         – In general, we typically recommend continuation of OCs and provision of appropriate perioperative thromboprophylaxis  (
         <a class="graphic graphic_table graphicRef77781" href="/z/d/graphic/77781.html" rel="external">
          table 3
         </a>
         ). In patients at higher risk for VTE who are undergoing high-risk surgery  (
         <a class="graphic graphic_table graphicRef83739" href="/z/d/graphic/83739.html" rel="external">
          table 4
         </a>
         ), discontinuation of OCs may be reasonable to mitigate the additional VTE risk; if the decision is made to discontinue, OCs should be stopped four weeks prior to surgery. Women who discontinue OCs that are used for contraceptive purposes should use an alternative method of birth control, which should be continued for the first week after resuming OCs postoperatively; if they cannot or prefer not to use an alternative method, continuing the OC is appropriate (with appropriate perioperative thromboprophylaxis). Prevention of thromboembolic disease in the surgical patient is discussed elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/1339.html" rel="external">
          "Prevention of venous thromboembolic disease in adult nonorthopedic surgical patients"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         We recommend a serum pregnancy test prior to surgery in all women of childbearing age.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Manufacturer product package inserts state that estrogen-containing OCs should be stopped four weeks prior to elective major operations and surgery to the legs, and they can be restarted at the first menses occurring at least two weeks after surgery or after full mobilization. However, evidence to support these recommendations is insufficient and these recommendations are inconsistent with typical clinical practice.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2487805884">
         <span class="h2">
          Estrogen-based hormone therapy
         </span>
        </p>
        <p class="headingAnchor" id="H21">
         <span class="h3">
          Postmenopausal hormone therapy
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Benefit/risk
         </strong>
         – The estrogen content of preparations used for postmenopausal hormone therapy (HT) is much lower than in oral contraceptive pills. However, use of oral HT, with either estrogen alone or estrogen plus a progestin, still appears to increase the risk of venous thromboembolism (VTE) [
         <a href="#rid81">
          81,82
         </a>
         ]. Although a case-control study did not find an increased risk of thromboembolism in those undergoing arthroplasty who received oral HT (odds ratio [OR] 0.66, 95% CI 0.35-1.18), the results may have been confounded by patients at lower risk for thromboembolism being more likely to be prescribed HT [
         <a href="#rid83">
          83
         </a>
         ]. Transdermal estrogen does not appear to increase risk for VTE in the general population, even among those with an elevated baseline risk for VTE [
         <a href="#rid84">
          84-86
         </a>
         ] (see
         <a class="medical medical_review" href="/z/d/html/7409.html" rel="external">
          "Menopausal hormone therapy and cardiovascular risk", section on 'Route of estrogen'
         </a>
         ); however, no data exist for surgical patients.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The risks associated with temporary discontinuation of hormone therapy are mainly discomfort from hot flashes and other menopausal symptoms.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Continue/discontinue
         </strong>
         – We usually individualize the decision to continue HT perioperatively based on the VTE risk of the procedure and the patient’s preference, but overall we feel the risk of continuing HT is relatively low  (
         <a class="graphic graphic_table graphicRef77781" href="/z/d/graphic/77781.html" rel="external">
          table 3
         </a>
         ). Ideally, individuals undergoing procedures associated with moderate to high risk for VTE should stop hormone therapy at least two weeks prior to elective surgery and resume treatment postoperatively once the period of elevated risk for VTE has resolved. HT can be continued uninterrupted for surgical procedures associated with a low risk of VTE. Definitions of low-, moderate-, and high-risk procedures, and appropriate VTE prophylaxis, are discussed elsewhere  (
         <a class="graphic graphic_table graphicRef83739" href="/z/d/graphic/83739.html" rel="external">
          table 4
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/1339.html" rel="external">
          "Prevention of venous thromboembolic disease in adult nonorthopedic surgical patients"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Manufacturers recommend that estrogens should be discontinued at least four to six weeks prior to a surgical procedure with increased risk of VTE or during periods of prolonged immobilization, but evidence to support this recommendation is insufficient, particularly for HT, as above.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2071760315">
         <span class="h3">
          Estrogen therapy in transgender women
         </span>
         <span class="headingEndMark">
          —
         </span>
         The approach to perioperative management of estrogen therapy in transgender women is reviewed elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/114517.html" rel="external">
          "Gender-affirming surgery: Male to female", section on 'Perioperative management of systemic estrogen therapy'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H22">
         <span class="h2">
          Selective estrogen receptor modulators
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Benefit/risk
         </strong>
         – The indications for use of selective estrogen receptor modulators (SERMs) such as
         <a class="drug drug_general" data-topicid="9972" href="/z/d/drug information/9972.html" rel="external">
          tamoxifen
         </a>
         and
         <a class="drug drug_general" data-topicid="9593" href="/z/d/drug information/9593.html" rel="external">
          raloxifene
         </a>
         include breast cancer treatment, breast cancer chemoprevention, and, at least for raloxifene, the prevention and treatment of osteoporosis (see
         <a class="medical medical_review" href="/z/d/html/756.html" rel="external">
          "Selective estrogen receptor modulators and aromatase inhibitors for breast cancer prevention"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2068.html" rel="external">
          "Selective estrogen receptor modulators for prevention and treatment of osteoporosis"
         </a>
         ). Both tamoxifen and raloxifene increase the risk of VTE [
         <a href="#rid87">
          87,88
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Brief discontinuation of SERMs used for the prevention/treatment of osteoporosis or the prevention of breast cancer is unlikely to result in harm. For patients with breast cancer who are being treated with SERMs, the risk of disease progression with preoperative cessation of treatment is a consideration.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Continue/discontinue
         </strong>
         – SERMs can be continued without interruption for low- and moderate-risk surgeries while providing appropriate VTE prophylaxis  (
         <a class="graphic graphic_table graphicRef77781" href="/z/d/graphic/77781.html" rel="external">
          table 3
         </a>
         ). Definitions of low-, moderate-, and high-risk procedures, and appropriate VTE prophylaxis, are discussed elsewhere  (
         <a class="graphic graphic_table graphicRef83739" href="/z/d/graphic/83739.html" rel="external">
          table 4
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/1339.html" rel="external">
          "Prevention of venous thromboembolic disease in adult nonorthopedic surgical patients"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         For surgeries with a high-risk of VTE, our approach depends upon the specific SERM and the indication for its use:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         For patients taking
         <a class="drug drug_general" data-topicid="9593" href="/z/d/drug information/9593.html" rel="external">
          raloxifene
         </a>
         for osteoporosis treatment/prevention or breast cancer prevention, we suggest discontinuing the medication three days prior to a surgical procedure associated with a high risk of VTE. The raloxifene can be resumed as soon as the period of elevated VTE risk is resolved. However, if the patient has taken the medication within three days of the procedure, we do
         <strong>
          not
         </strong>
         recommend postponing the surgery for this reason; the procedure can be done as planned and appropriate VTE prophylaxis provided. (See
         <a class="medical medical_review" href="/z/d/html/1339.html" rel="external">
          "Prevention of venous thromboembolic disease in adult nonorthopedic surgical patients"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         For patients taking
         <a class="drug drug_general" data-topicid="9972" href="/z/d/drug information/9972.html" rel="external">
          tamoxifen
         </a>
         for breast cancer prevention (ie, in women without a history of breast cancer), we suggest discontinuing the medication two weeks prior to a surgical procedure associated with a high risk of VTE. The tamoxifen can be resumed as soon as the period of elevated VTE risk has resolved. However, if the patient has taken the medication within two weeks of the procedure, we do
         <strong>
          not
         </strong>
         recommend postponing the surgery for this reason; the procedure can be done as planned and appropriate VTE prophylaxis provided. (See
         <a class="medical medical_review" href="/z/d/html/1339.html" rel="external">
          "Prevention of venous thromboembolic disease in adult nonorthopedic surgical patients"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         For patients taking a SERM (eg,
         <a class="drug drug_general" data-topicid="9972" href="/z/d/drug information/9972.html" rel="external">
          tamoxifen
         </a>
         ) for breast cancer treatment, the decision to discontinue is more difficult, and consultation with an oncologist is recommended. We typically recommend continuing SERMs in this setting while providing appropriate VTE prophylaxis. (See
         <a class="medical medical_review" href="/z/d/html/1339.html" rel="external">
          "Prevention of venous thromboembolic disease in adult nonorthopedic surgical patients"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The package insert for
         <a class="drug drug_general" data-topicid="9972" href="/z/d/drug information/9972.html" rel="external">
          tamoxifen
         </a>
         states that in the case of surgery and immobility, the medication should only be stopped if the risk of tamoxifen-induced thrombosis clearly outweighs the risks associated with interrupting treatment. If continued, all patients should receive appropriate thrombosis prophylactic measures. The manufacturers of
         <a class="drug drug_general" data-topicid="9593" href="/z/d/drug information/9593.html" rel="external">
          raloxifene
         </a>
         , however, recommend stopping it at least three days before surgery.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H23">
         <span class="h2">
          Drugs used for thyroid disease
         </span>
         <span class="headingEndMark">
          —
         </span>
         The management of medications to control hypothyroid and hyperthyroid states is discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/7858.html" rel="external">
          "Nonthyroid surgery in the patient with thyroid disease"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Continue/discontinue
         </strong>
         – We recommend perioperative continuation of therapy for both hyperthyroidism and hypothyroidism.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In the case that a patient cannot take oral medications for several days, the approach depends upon the thyroid medication:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Thyroxine (T4) has a long half-life, and patients on chronic T4 therapy who are unable to take oral medication for several days do not need parenteral T4. If oral T4 cannot be resumed within five to seven days, it should then be administered parenterally (intravenously or intramuscularly).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         The antithyroid thionamide medications (
         <a class="drug drug_general" data-topicid="9627" href="/z/d/drug information/9627.html" rel="external">
          methimazole
         </a>
         and
         <a class="drug drug_general" data-topicid="9830" href="/z/d/drug information/9830.html" rel="external">
          propylthiouracil
         </a>
         ) have a very short half-life. The decision on how long to hold antithyroid medications for a patient who is unable to take oral medications must be individualized based upon several factors, including the patient's history of thyroid disease and length of previous treatment with antithyroid medications. (See
         <a class="medical medical_review" href="/z/d/html/7858.html" rel="external">
          "Nonthyroid surgery in the patient with thyroid disease", section on 'Preexisting hyperthyroidism'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Formulations/alternatives
         </strong>
         – T4 can be given intravenously or intramuscularly. When administered parenterally, the dose of T4 should be reduced to approximately 80 percent of the patient's usual oral dose to reflect the fraction of oral T4 that is absorbed.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         There are rectal (suppository and retention enema) options for administration of either of the antithyroid medications  (
         <a class="graphic graphic_table graphicRef79245" href="/z/d/graphic/79245.html" rel="external">
          table 5
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H24">
         <span class="h2">
          Drugs used for osteoporosis/osteopenia
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Benefit/risk
         </strong>
         – Bisphosphonate use, especially in malignancy, has been associated with osteonecrosis of the jaw in patients undergoing dental surgery. The absolute risk is very low, but osteonecrosis is difficult to manage. The duration of effect of bisphosphonates on bone remodeling is long, and the discontinuation of these agents for weeks or even months before surgery has not been shown to decrease the risk of osteonecrosis. Likewise, there is no evidence that short-term discontinuation of these agents results in reduction in treatment efficacy for prevention of osteoporotic bone fractures.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Continue/discontinue
         </strong>
         – We recommend withholding bisphosphonates only on the morning of surgery, as they are typically taken with at least 8 ounces of water and the patient is supposed to remain upright for at least 30 minutes and until after eating a meal.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Guidelines from the American Association of Oral and Maxillofacial Surgeons recommend proceeding as usual with dental surgery in patients who have been treated with oral bisphosphonates for less than four years and have no clinical risk factors [
         <a href="#rid89">
          89
         </a>
         ]. They suggest discontinuing bisphosphonates for two months prior to performing the dental surgery if a patient has been treated for more than four years or has taken concomitant glucocorticoids. Bisphosphonates are restarted when the bone has healed.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         We generally agree with these guidelines and advise that, for patients undergoing dental surgery, bisphosphonates not be held in advance of the procedure nor dental surgery delayed since the absolute risk of jaw osteonecrosis is low and the benefit of holding the medication in advance is not clear. For patients believed to be at very high risk due to need for extensive bony surgery, concomitant glucocorticoid or chemotherapy, or long-term bisphosphonate use, a delay of surgery for two months is reasonable, although these cases are uncommon. (See
         <a class="medical medical_review" href="/z/d/html/104424.html" rel="external">
          "Risks of bisphosphonate therapy in patients with osteoporosis", section on 'Osteonecrosis of the jaw'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H25">
         <span class="h1">
          MEDICATIONS AFFECTING HEMOSTASIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Many patients undergoing surgery are taking medications that are intended to impair normal hemostasis or appropriate thrombosis (eg,
         <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">
          warfarin
         </a>
         ,
         <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">
          aspirin
         </a>
         , or other antiplatelet agents), or take medications for another indication that have an unintended effect on hemostasis, such as nonsteroidal antiinflammatory drugs (NSAIDs)  (
         <a class="graphic graphic_table graphicRef68515" href="/z/d/graphic/68515.html" rel="external">
          table 6
         </a>
         ).
        </p>
        <p class="headingAnchor" id="H26">
         <span class="h2">
          Aspirin
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Benefit/risk
         </strong>
         –
         <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">
          Aspirin
         </a>
         irreversibly inhibits platelet cyclooxygenase, which may increase intraoperative blood loss and hemorrhagic complications [
         <a href="#rid90">
          90-95
         </a>
         ]. However, the same effect can help to prevent perioperative vascular complications, in particular cardiac and thromboembolic complications. The perioperative benefits and risks of aspirin depend on the patient's indication for aspirin and the planned surgery.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         For example, observational studies suggest that withdrawal of
         <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">
          aspirin
         </a>
         preoperatively is associated with increased in-hospital mortality in patients undergoing coronary artery bypass graft surgery (CABG) [
         <a href="#rid96">
          96,97
         </a>
         ]. However, in patients undergoing noncardiac surgery, the large randomized POISE-2 trial found that perioperative aspirin increases bleeding risk but does not improve cardiovascular or mortality outcomes [
         <a href="#rid98">
          98
         </a>
         ]. A substudy of the trial also found no benefit for perioperative aspirin administration at reducing the risk of acute kidney injury [
         <a href="#rid24">
          24
         </a>
         ] and no benefit for prevention of venous thromboembolism (VTE), although two-thirds of the patients also received anticoagulants and there were few VTE events overall [
         <a href="#rid99">
          99
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/1556.html" rel="external">
          "Coronary artery bypass surgery: Perioperative medical management", section on 'Aspirin'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6615.html" rel="external">
          "Management of cardiac risk for noncardiac surgery", section on 'Antiplatelet therapy'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Continue/discontinue
         </strong>
         – Recommendations to continue or discontinue
         <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">
          aspirin
         </a>
         vary depending on what surgery is planned and the patient’s indication for aspirin. As examples:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Patients undergoing CABG (see
         <a class="medical medical_review" href="/z/d/html/1556.html" rel="external">
          "Coronary artery bypass surgery: Perioperative medical management", section on 'Aspirin'
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Patients undergoing vascular surgery (see
         <a class="medical medical_review" href="/z/d/html/8193.html" rel="external">
          "Carotid endarterectomy", section on 'Antiplatelet therapy'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/15221.html" rel="external">
          "Surgical and endovascular repair of popliteal artery aneurysm", section on 'Antiplatelet therapy'
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Patients who have undergone percutaneous coronary interventions and are on
         <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">
          aspirin
         </a>
         as part of dual antiplatelet therapy (see
         <a class="medical medical_review" href="/z/d/html/86233.html" rel="external">
          "Noncardiac surgery after percutaneous coronary intervention", section on 'Our approach'
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Patients who have recently had an acute coronary syndrome (see
         <a class="medical medical_review" href="/z/d/html/6615.html" rel="external">
          "Management of cardiac risk for noncardiac surgery", section on 'For recent acute coronary syndrome including myocardial infarction'
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Patients with cardiac risk who are undergoing non-cardiovascular surgery (not including cataract surgery) (see
         <a class="medical medical_review" href="/z/d/html/6615.html" rel="external">
          "Management of cardiac risk for noncardiac surgery", section on 'Antiplatelet therapy'
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Patients undergoing cataract surgery (see
         <a class="medical medical_review" href="/z/d/html/6904.html" rel="external">
          "Cataract in adults", section on 'Aspirin and other antiplatelet agents'
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">
          Aspirin
         </a>
         can be safely continued in most patients undergoing minor dental surgery or dermatologic procedures. For other patients taking aspirin for secondary prevention, the risks and benefits of perioperative aspirin should be discussed with the patient, surgeon, cardiologist, or neurologist.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Guidelines from the American Society of Regional Anesthesia (ASRA) indicate that NSAIDs, including
         <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">
          aspirin
         </a>
         , do not create a level of risk that will interfere with the performance of neuraxial blocks, and should not impact catheter techniques, timing of neuraxial catheter removal, or postoperative monitoring [
         <a href="#rid100">
          100
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Formulations/alternatives
         </strong>
         –
         <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">
          Aspirin
         </a>
         is not available in parenteral forms but is available as a rectal suppository for patients who are felt to need ongoing therapy but cannot take oral medication.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H27">
         <span class="h2">
          Other antiplatelet agents
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Benefit/risk
         </strong>
         – The platelet P2Y
         <sub>
          12
         </sub>
         receptor blockers
         <a class="drug drug_general" data-topicid="8921" href="/z/d/drug information/8921.html" rel="external">
          clopidogrel
         </a>
         ,
         <a class="drug drug_general" data-topicid="9533" href="/z/d/drug information/9533.html" rel="external">
          prasugrel
         </a>
         ,
         <a class="drug drug_general" data-topicid="16784" href="/z/d/drug information/16784.html" rel="external">
          ticagrelor
         </a>
         , and
         <a class="drug drug_general" data-topicid="9996" href="/z/d/drug information/9996.html" rel="external">
          ticlopidine
         </a>
         are used in patients who have had previous cerebrovascular events, recent acute coronary syndromes, or recent percutaneous coronary or vascular interventions with stenting. Issues related to continuation or discontinuation, as well as postoperative reinstitution of clopidogrel and other P2Y
         <sub>
          12
         </sub>
         receptor blockers, are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/86233.html" rel="external">
          "Noncardiac surgery after percutaneous coronary intervention", section on 'Our approach'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <a class="drug drug_general" data-topicid="9377" href="/z/d/drug information/9377.html" rel="external">
          Dipyridamole
         </a>
         has both vasodilator and antiplatelet activity. With the publication of the ESPS-2 trial [
         <a href="#rid101">
          101
         </a>
         ], its use has become more common in patients with past stroke or transient ischemic attack (TIA). The half-life of the modified-release preparation is approximately 10 hours. (See
         <a class="medical medical_review" href="/z/d/html/1086.html" rel="external">
          "Long-term antithrombotic therapy for the secondary prevention of ischemic stroke"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1119.html" rel="external">
          "Overview of secondary prevention for specific causes of ischemic stroke and transient ischemic attack"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <a class="drug drug_general" data-topicid="8872" href="/z/d/drug information/8872.html" rel="external">
          Cilostazol
         </a>
         is a selective phosphodiesterase-3 enzyme inhibitor with weaker reversible antiplatelet activity than the P2Y
         <sub>
          12
         </sub>
         receptor blockers and is used primarily for treatment of claudication symptoms. Its half-life is approximately 21 hours. (See
         <a class="medical medical_review" href="/z/d/html/8210.html" rel="external">
          "Management of claudication due to peripheral artery disease"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Continue/discontinue
         </strong>
         – Many patients take both
         <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">
          aspirin
         </a>
         and platelet P2Y
         <sub>
          12
         </sub>
         receptor blocker therapy to prevent coronary stent thrombosis. Premature cessation of dual antiplatelet therapy is associated with an increased risk for stent thrombosis. Management of such patients is discussed elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/86233.html" rel="external">
          "Noncardiac surgery after percutaneous coronary intervention"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         There are no data on the safety of
         <a class="drug drug_general" data-topicid="9377" href="/z/d/drug information/9377.html" rel="external">
          dipyridamole
         </a>
         if continued in the perioperative period. Like
         <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">
          aspirin
         </a>
         , factors to consider in deciding whether to continue or hold dipyridamole reflect a balance between the risk of bleeding and risk of ischemic events. If discontinued, the drug should be stopped at least two days before surgery. Aggrenox (combination aspirin and dipyridamole) should be discontinued 7 to 10 days before surgery.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <a class="drug drug_general" data-topicid="8872" href="/z/d/drug information/8872.html" rel="external">
          Cilostazol
         </a>
         should be discontinued for at least two to three days prior to elective surgery, but the manufacturer recommends stopping it at least five days before. Claudication symptoms may recur when the medication is stopped, but should respond once cilostazol is reinitiated postoperatively.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H28">
         <span class="h2">
          Nonsteroidal antiinflammatory drugs
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Benefit/risk
         </strong>
         – The antiplatelet effects of NSAIDs are due to reversible inhibition of cyclooxygenase (COX)-1, an isoform of cyclooxygenase, leading to decreased production of thromboxane A2 (TxA2). TxA2 is released by platelets in response to a number of agonists, leading to platelet aggregation (see
         <a class="medical medical_review" href="/z/d/html/7991.html" rel="external">
          "Nonselective NSAIDs: Overview of adverse effects", section on 'Antiplatelet effects'
         </a>
         ). These antiplatelet effects increase the bleeding risk perioperatively but, like
         <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">
          aspirin
         </a>
         , may reduce the risk of perioperative vascular events [
         <a href="#rid102">
          102
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The selective COX-2 inhibitors, such as
         <a class="drug drug_general" data-topicid="8847" href="/z/d/drug information/8847.html" rel="external">
          celecoxib
         </a>
         , have minimal effects on platelet function [
         <a href="#rid103">
          103
         </a>
         ], although the potential for renal toxicity remains [
         <a href="#rid104">
          104
         </a>
         ]. Most selective COX-2 inhibitors and nonselective NSAIDs appear to have deleterious cardiovascular effects. (See
         <a class="medical medical_review" href="/z/d/html/7992.html" rel="external">
          "Overview of COX-2 selective NSAIDs"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7968.html" rel="external">
          "NSAIDs: Adverse cardiovascular effects"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Non-acetylated nonsteroidals, such as
         <a class="drug drug_general" data-topicid="9876" href="/z/d/drug information/9876.html" rel="external">
          salsalate
         </a>
         , do not have an antiplatelet effect.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Continue/discontinue
         </strong>
         – On balance, we recommend discontinuing NSAIDs, including selective COX-2 inhibitors, prior to surgery. For certain patients, however, pain control may not permit extensive periods of time without these medications, and consultation with the surgeon regarding risk of procedural bleeding should be weighed against pain control. For patients whose pain is dramatically responsive to COX-2 inhibitors, consideration may be given to continuing these agents since they have minimal effects on platelet function.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Although some experts recommend discontinuing NSAIDs based upon drug-specific elimination half-lives [
         <a href="#rid105">
          105
         </a>
         ], the elimination half-life correlates poorly with cyclooxygenase inhibition and effects on platelet aggregation [
         <a href="#rid106">
          106,107
         </a>
         ]. In healthy individuals receiving
         <a class="drug drug_general" data-topicid="8547" href="/z/d/drug information/8547.html" rel="external">
          ibuprofen
         </a>
         for one week, platelet function appears to return to normal within 24 hours after the last dose [
         <a href="#rid108">
          108
         </a>
         ]. However, the relationship between time of discontinuation of NSAIDs with intra- and postoperative clinical bleeding is not well-defined. For most NSAIDs, platelet function normalizes within three days of discontinuation [
         <a href="#rid109">
          109
         </a>
         ], suggesting that NSAIDs should generally be discontinued at least three days before surgery; ibuprofen can be stopped 24 hours prior to surgery.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Nonacetylated NSAIDs (eg,
         <a class="drug drug_general" data-topicid="9357" href="/z/d/drug information/9357.html" rel="external">
          diflunisal
         </a>
         ,
         <a class="drug drug_general" data-topicid="9876" href="/z/d/drug information/9876.html" rel="external">
          salsalate
         </a>
         ) can be continued in the perioperative period and may be considered as alternatives to other NSAIDs for pain control. The nonacetylated NSAIDs have a slow onset of effect which may limit their usefulness in the perioperative period.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Formulations/alternatives
         </strong>
         – Intravenous preparations of
         <a class="drug drug_general" data-topicid="8591" href="/z/d/drug information/8591.html" rel="external">
          ketorolac
         </a>
         and
         <a class="drug drug_general" data-topicid="8547" href="/z/d/drug information/8547.html" rel="external">
          ibuprofen
         </a>
         are available for short-term treatment of moderate acute pain and febrile conditions when oral administration is not available and as an adjunct to other analgesics for the treatment of moderate to severe postoperative pain. Patients should be well-hydrated and without significant renal impairment.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Intravenous
         <a class="drug drug_general" data-topicid="9242" href="/z/d/drug information/9242.html" rel="external">
          acetaminophen
         </a>
         (paracetamol) is also available and is a useful alternative for patients at risk for NSAID-associated gastropathy or renal impairment. Selection and use of the non-opiate analgesics is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/1606.html" rel="external">
          "Sedative-analgesia in ventilated adults: Management strategies, agent selection, monitoring, and withdrawal"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H836121679">
         <span class="h2">
          Rheological agents
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Benefit/risk
         </strong>
         – Rheological (hemorrheologic) agents such as
         <a class="drug drug_general" data-topicid="9757" href="/z/d/drug information/9757.html" rel="external">
          pentoxifylline
         </a>
         are not anticoagulants, but they are believed to improve blood flow in the microcirculation by lowering blood viscosity, increasing erythrocyte flexibility, and reducing neutrophil adhesion and activation. Pentoxifylline can be used for treatment of symptomatic peripheral arterial disease (ie, intermittent claudication), venous ulcers, and alcoholic hepatitis.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Continue/discontinue
         </strong>
         – Although there are no high-quality data informing this approach, based on the short half-life of the agent, we typically discontinue the medication preoperatively, with the last dose taken the morning of surgery. However, due to the lack of evidence of increased bleeding, we would generally advise proceeding with surgery even if the medication was not discontinued. For patients being treated for alcoholic hepatitis, we would consult with the prescribing hepatologist to ensure that temporary discontinuation (as well as any surgery) is safe for the patient.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H29">
         <span class="h2">
          Anticoagulants
         </span>
         <span class="headingEndMark">
          —
         </span>
         The perioperative management of patients taking
         <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">
          warfarin
         </a>
         and other oral anticoagulants is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/1312.html" rel="external">
          "Perioperative management of patients receiving anticoagulants"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1744185635">
         <span class="h1">
          MEDICATIONS AFFECTING KIDNEY FUNCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Several medications and agents used during the perioperative period may lead to acute kidney injury, including nonsteroidal antiinflammatory drugs (NSAIDs), angiotensin-converting enzyme (ACE) inhibitors, angiotensin II receptor blockers (ARBs), diuretics, antibiotics (eg, aminoglycosides,
         <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">
          vancomycin
         </a>
         ), and intravenous contrast agents [
         <a href="#rid110">
          110
         </a>
         ]. The benefits and risks vary based on each drug. (See
         <a class="medical medical_review" href="/z/d/html/3816.html" rel="external">
          "Major side effects of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers", section on 'Reduction in GFR'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7176.html" rel="external">
          "Epidemiology and pathogenesis of analgesic-related chronic kidney disease", section on 'Nonsteroidal antiinflammatory drugs'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/483.html" rel="external">
          "Aminoglycosides", section on 'Nephrotoxicity'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/479.html" rel="external">
          "Beta-lactam antibiotics: Mechanisms of action and resistance and adverse effects", section on 'Renal reactions'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7221.html" rel="external">
          "Prevention of contrast-associated acute kidney injury related to angiography"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2310.html" rel="external">
          "Loop diuretics: Dosing and major side effects", section on 'Diuresis related'
         </a>
         .)
        </p>
        <p>
         Optimizing volume status and medications to prevent acute tubular necrosis are discussed elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/7224.html" rel="external">
          "Possible prevention and therapy of ischemic acute tubular necrosis", section on 'Prevention'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H21841595">
         <span class="h1">
          PSYCHOTROPIC AGENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The perioperative management of patients taking psychotropic agents varies with the class of drugs used  (
         <a class="graphic graphic_table graphicRef66948" href="/z/d/graphic/66948.html" rel="external">
          table 7
         </a>
         ) and severity of mental illness. Evidence-based guidelines for these drugs are lacking; data are primarily derived from case reports and open trials [
         <a href="#rid111">
          111
         </a>
         ]. Perioperative decisions about use of these drugs must balance their potential for side effects and interaction with anesthetic agents with psychiatric and physiologic consequences of withdrawal of these agents. In general, psychotropic medications for treatment of patients with serious or unstable mental illness should be continued throughout the perioperative period to avoid psychiatric decompensation. However, the optimal choice of anesthesia and analgesia in combination with many psychotropic agents is unknown. Other than antipsychotics, many psychotropic agents do not have a parenteral delivery mode. Appropriate pharmacologic management includes consideration of parenteral alternatives of the same or different class to maintain mood and behavior stability.
        </p>
        <p class="headingAnchor" id="H31">
         <span class="h2">
          Tricyclic and tetracyclic antidepressants
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Benefit/risk
         </strong>
         – Cyclic antidepressants inhibit the uptake of norepinephrine and serotonin at the synaptic cleft. Unlike most newer antidepressants, cyclic antidepressants lower the seizure threshold and possess significant anticholinergic, antihistaminic, and alpha-1 blocking properties. These agents delay gastric emptying, prolong the QTc interval, and may increase the risk for arrhythmias in combination with some volatile anesthetics or sympathomimetic agents, although literature to support this concern is scant. Abrupt withdrawal of tricyclic antidepressants can lead to insomnia, nausea, headache, increased salivation, and sweating and should be avoided if feasible [
         <a href="#rid112">
          112
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/1717.html" rel="external">
          "Tricyclic and tetracyclic drugs: Pharmacology, administration, and side effects"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Cyclic antidepressants can amplify the systemic pressor effects of norepinephrine and epinephrine; however, use with epinephrine-containing local anesthesia is generally safe. Use with
         <a class="drug drug_general" data-topicid="8983" href="/z/d/drug information/8983.html" rel="external">
          atropine
         </a>
         or
         <a class="drug drug_general" data-topicid="9915" href="/z/d/drug information/9915.html" rel="external">
          scopolamine
         </a>
         may increase postoperative confusion. Due to additive serotoninergic effects, use with
         <a class="drug drug_general" data-topicid="10010" href="/z/d/drug information/10010.html" rel="external">
          tramadol
         </a>
         and
         <a class="drug drug_general" data-topicid="9608" href="/z/d/drug information/9608.html" rel="external">
          meperidine
         </a>
         is not recommended. (See
         <a class="medical medical_review" href="/z/d/html/301.html" rel="external">
          "Serotonin syndrome (serotonin toxicity)"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Continue/discontinue
         </strong>
         – Most textbooks and journals recommend continuing these agents in the perioperative period [
         <a href="#rid2">
          2
         </a>
         ]. However, the US Food and Drug Administration (FDA) and some experts advise that tricyclic antidepressants (
         <a class="drug drug_general" data-topicid="8554" href="/z/d/drug information/8554.html" rel="external">
          imipramine
         </a>
         ,
         <a class="drug drug_general" data-topicid="8605" href="/z/d/drug information/8605.html" rel="external">
          amitriptyline
         </a>
         ,
         <a class="drug drug_general" data-topicid="9711" href="/z/d/drug information/9711.html" rel="external">
          nortriptyline
         </a>
         ,
         <a class="drug drug_general" data-topicid="9329" href="/z/d/drug information/9329.html" rel="external">
          desipramine
         </a>
         , and
         <a class="drug drug_general" data-topicid="9283" href="/z/d/drug information/9283.html" rel="external">
          clomipramine
         </a>
         ) be discontinued prior to elective surgery, when possible, and this information is provided in package labelling for these medications [
         <a href="#rid111">
          111
         </a>
         ]. The stability of the patient's depression should be considered prior to tapering or discontinuing the medication to avoid worsening of depression. If depression is moderate or severe, best practice would be to continue the antidepressant and notify the anesthesia team to monitor for cardiac arrhythmias in the perioperative period. If depression is mild, the antidepressant is not felt to be essential for short-term quality of life, and if arrhythmias are of concern, the agent should be tapered to minimize the chance of withdrawal.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         We generally recommend continuation of cyclic agents throughout the perioperative period, in particular for patients on high doses without cardiac disease. For patients on low doses or in whom the risk of perioperative arrhythmia is increased, the agents should be tapered off over a period of 7 to 14 days before surgery. The elimination half-life of various cyclic antidepressants ranges from one to three days or more. For detail, refer to the
         <a class="external" href="/drug-interactions">
          drug interactions program
         </a>
         included with UpToDate.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Formulations/alternatives
         </strong>
         – Parenteral
         <a class="drug drug_general" data-topicid="8605" href="/z/d/drug information/8605.html" rel="external">
          amitriptyline
         </a>
         and
         <a class="drug drug_general" data-topicid="9283" href="/z/d/drug information/9283.html" rel="external">
          clomipramine
         </a>
         preparations are available in many countries, but not in the United States. In consultation with the patient's psychiatrist, consider substitution of another class of agent, such as a selective serotonin reuptake inhibitor, if it is felt that the tricyclic antidepressant is truly contraindicated.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H32">
         <span class="h2">
          Selective serotonin reuptake inhibitors
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Benefit/risk
         </strong>
         – Selective serotonin reuptake inhibitors (SSRIs) may increase bleeding risk and the consequent need for transfusion with surgery, perhaps because of their effects on platelet aggregation. Bleeding risk with SSRIs has been documented primarily in association with antiplatelet or nonsteroidal antiinflammatory drug (NSAID) use [
         <a href="#rid113">
          113-115
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/14675.html" rel="external">
          "Selective serotonin reuptake inhibitors: Pharmacology, administration, and side effects", section on 'Bleeding'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Results from several studies differ regarding risk and type of surgery. In the largest multicenter study (375 hospitals, more than 530,000 patients), after adjusting for multiple morbidities, patients who received SSRIs had a small increase in risk of perioperative bleeding (odds ratio [OR] 1.09, 95% CI 1.04-1.15) [
         <a href="#rid116">
          116
         </a>
         ]. A prospective cohort study involving 767 patients undergoing cardiac, vascular, spinal, and intracranial surgery at two academic medical centers found that preoperative use of SSRIs was associated with a twofold increase (OR = 2.2; 95% CI 1.2-3.98) in exposure to allogeneic hemostatic blood products in surgical patients at high risk for perioperative bleeding [
         <a href="#rid117">
          117
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Smaller studies suggest that the risk in orthopedic surgery is likely to be clinically insignificant, if present. One retrospective study in total hip arthroplasty patients noted a statistically significant 95 mL higher mean blood loss in patients on SSRIs compared with non-serotonergic antidepressants and controls; however, the authors felt this was of limited clinical significance [
         <a href="#rid118">
          118
         </a>
         ]. An association between bleeding risk and SSRI continuation in patients undergoing orthopedic surgeries was not found in other studies that controlled for confounding variables (eg, use of NSAIDs) [
         <a href="#rid119">
          119
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Several studies noted no increased risk of bleeding with coronary artery bypass procedures and with plastic surgery [
         <a href="#rid120">
          120-123
         </a>
         ]. A large metaanalysis found SSRIs to be associated with an increased risk of transfusion but not an increase in mortality [
         <a href="#rid124">
          124
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Stopping SSRIs could lead to exacerbation of mood and other disorders. The washout period for SSRIs may be as long as three weeks, and reinitiation may not lead to clinical benefit for several weeks. Half-life varies widely from 15 hours (ie,
         <a class="drug drug_general" data-topicid="9743" href="/z/d/drug information/9743.html" rel="external">
          paroxetine
         </a>
         ,
         <a class="drug drug_general" data-topicid="8474" href="/z/d/drug information/8474.html" rel="external">
          fluvoxamine
         </a>
         ,
         <a class="drug drug_general" data-topicid="9886" href="/z/d/drug information/9886.html" rel="external">
          sertraline
         </a>
         ) up to seven days (
         <a class="drug drug_general" data-topicid="8465" href="/z/d/drug information/8465.html" rel="external">
          fluoxetine
         </a>
         ). Abrupt withdrawal of short-acting SSRIs should be avoided, as it can cause a discontinuation syndrome including dizziness, chills, muscle aches, and anxiety (see
         <a class="medical medical_review" href="/z/d/html/105323.html" rel="external">
          "Discontinuing antidepressant medications in adults"
         </a>
         ). Determining whether perioperative continuation or withdrawal of SSRIs produces a net clinical benefit requires randomized controlled trials.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Continue/discontinue
         </strong>
         – For most patients, we recommend continuing SSRI therapy through the perioperative period. The decision to withhold SSRIs perioperatively should balance the consequences of bleeding with the severity of the underlying psychiatric disorder.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         For patients undergoing surgical procedures with substantial risks of postoperative bleeding that could lead to significant morbidity (such as central nervous system procedures), or in patients requiring ongoing antiplatelet therapy for secondary prevention (eg,
         <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">
          aspirin
         </a>
         and thienopyridine for a drug-eluting cardiac stent), consider discontinuing SSRIs by tapering several weeks prior to surgery and starting an alternative antidepressant regimen, in consultation with a psychiatrist if possible. Patients with severe mood disorders and those undergoing surgery with low to moderate risks of abnormal bleeding should generally be maintained on SSRIs through surgery.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Antiplatelet agents should be discontinued preoperatively if at all possible in patients taking SSRIs. If
         <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">
          aspirin
         </a>
         or thienopyridine therapy is required for secondary prevention through surgery (eg, presence of a drug-eluting cardiac stent), then the SSRI should be discontinued in advance of surgery and an alternative antidepressant regimen considered, in consultation with a psychiatrist if possible.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H48312957">
         <span class="h2">
          Selective norepinephrine reuptake inhibitors and bupropion
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Benefit/risk
         </strong>
         – There are limited data regarding selective norepinephrine reuptake inhibitor (SNRI) agents in the perioperative period. A retrospective study of 4136 patients undergoing coronary artery bypass graft (CABG) surgery showed that SNRI use was associated with an increased risk of renal dysfunction and prolonged ventilation but not bleeding events or long-term mortality [
         <a href="#rid121">
          121
         </a>
         ]. This has not been replicated in other studies.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         No literature exists regarding perioperative considerations with
         <a class="drug drug_general" data-topicid="9171" href="/z/d/drug information/9171.html" rel="external">
          bupropion
         </a>
         .
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Continue/discontinue
         </strong>
         – Considerations regarding cessation versus continuation in the perioperative period should be similar as with SSRIs. (See
         <a class="local">
          'Selective serotonin reuptake inhibitors'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H33">
         <span class="h2">
          Monoamine oxidase inhibitors
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Benefit/risk
         </strong>
         – Nonselective irreversible monoamine oxidase (MAO) inhibitors for use as antidepressants (
         <a class="drug drug_general" data-topicid="8991" href="/z/d/drug information/8991.html" rel="external">
          isocarboxazid
         </a>
         , pargyline,
         <a class="drug drug_general" data-topicid="9762" href="/z/d/drug information/9762.html" rel="external">
          phenelzine
         </a>
         , and
         <a class="drug drug_general" data-topicid="10012" href="/z/d/drug information/10012.html" rel="external">
          tranylcypromine
         </a>
         ) are prescribed far less commonly than other antidepressants but are used in patients with refractory mood disorders in whom withdrawal and recurrent depression may be problematic. MAO inhibitors are also used for treatment of conditions other than depression  (
         <a class="graphic graphic_table graphicRef78294" href="/z/d/graphic/78294.html" rel="external">
          table 8
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Use of nonselective MAO inhibitors results in the accumulation of biogenic amines in central and autonomic system neurons. Concomitant administration of sympathomimetic agents, like
         <a class="drug drug_general" data-topicid="9114" href="/z/d/drug information/9114.html" rel="external">
          ephedrine
         </a>
         during anesthesia, can result in massive release of stored norepinephrine and severe hypertensive crisis. In addition, two types of central nervous system (CNS) reactions may occur relevant to surgery and anesthesia. The "Type I" reaction occurs with the administration of anticholinergics (such as
         <a class="drug drug_general" data-topicid="8893" href="/z/d/drug information/8893.html" rel="external">
          dextromethorphan
         </a>
         ) and
         <a class="drug drug_general" data-topicid="9608" href="/z/d/drug information/9608.html" rel="external">
          meperidine
         </a>
         with MAO inhibitors, leading to a serotonin syndrome (agitation, headache, fever, and seizures, with possibility of coma and death) [
         <a href="#rid111">
          111
         </a>
         ] (see
         <a class="medical medical_review" href="/z/d/html/301.html" rel="external">
          "Serotonin syndrome (serotonin toxicity)"
         </a>
         ). The "Type II" reaction occurs when the MAO inhibitor inhibits hepatic microsomal enzymes involved in opiate metabolism, subsequently leading to accumulation of free narcotic, sedation, respiratory depression, and cardiovascular collapse [
         <a href="#rid125">
          125
         </a>
         ]. We recommend the use of lower-risk opioids, including
         <a class="drug drug_general" data-topicid="9788" href="/z/d/drug information/9788.html" rel="external">
          morphine
         </a>
         ,
         <a class="drug drug_general" data-topicid="9291" href="/z/d/drug information/9291.html" rel="external">
          codeine
         </a>
         ,
         <a class="drug drug_general" data-topicid="9170" href="/z/d/drug information/9170.html" rel="external">
          buprenorphine
         </a>
         ,
         <a class="drug drug_general" data-topicid="9733" href="/z/d/drug information/9733.html" rel="external">
          oxymorphone
         </a>
         , or
         <a class="drug drug_general" data-topicid="8538" href="/z/d/drug information/8538.html" rel="external">
          hydromorphone
         </a>
         , to mitigate risk for a Type I reaction. Patients continuing MAO inhibitors requiring opioid therapy with higher-risk agents (
         <a class="drug drug_general" data-topicid="8441" href="/z/d/drug information/8441.html" rel="external">
          fentanyl
         </a>
         ,
         <a class="drug drug_general" data-topicid="9729" href="/z/d/drug information/9729.html" rel="external">
          oxycodone
         </a>
         or
         <a class="drug drug_general" data-topicid="9623" href="/z/d/drug information/9623.html" rel="external">
          methadone
         </a>
         should be monitored closely for CNS depressive effects.
         <a class="drug drug_general" data-topicid="9762" href="/z/d/drug information/9762.html" rel="external">
          Phenelzine
         </a>
         may prolong the effect of
         <a class="drug drug_general" data-topicid="9952" href="/z/d/drug information/9952.html" rel="external">
          succinylcholine
         </a>
         . Use with epinephrine-containing local anesthetics is generally safe.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         A designated MAO-safe anesthetic technique has been reported for use in patients unable to discontinue the MAO inhibitor, such as in emergency procedures [
         <a href="#rid126">
          126
         </a>
         ]. This involves avoidance of
         <a class="drug drug_general" data-topicid="9608" href="/z/d/drug information/9608.html" rel="external">
          meperidine
         </a>
         and
         <a class="drug drug_general" data-topicid="8893" href="/z/d/drug information/8893.html" rel="external">
          dextromethorphan
         </a>
         and cautious use of only direct acting intravenous sympathomimetic agents such as norepinephrine, epinephrine,
         <a class="drug drug_general" data-topicid="9768" href="/z/d/drug information/9768.html" rel="external">
          phenylephrine
         </a>
         , and
         <a class="drug drug_general" data-topicid="8578" href="/z/d/drug information/8578.html" rel="external">
          isoproterenol
         </a>
         .
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Continue/discontinue
         </strong>
         – The decision to continue or withhold nonselective MAO inhibitors before surgery requires close collaboration with the anesthesiologist and psychiatrist.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         MAO inhibitors generally should be continued when two criteria are met: (1) the anesthesiologist is comfortable with use of MAO-safe procedures; and (2) the psychiatrist believes temporary withdrawal of the agent will exacerbate or precipitate a depressive syndrome.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In the absence of either criteria, we recommend discontinuing MAO inhibitors before surgery. Many MAO inhibitors are irreversible antagonists, and recovery of MAO function requires two weeks after discontinuation of the drug. Thus, patients should taper and discontinue MAO inhibitors two weeks before elective surgery. An alternative drug regimen for depression, such as tricyclic antidepressant or SSRI therapy, may be used for the perioperative period.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         If MAO inhibitors are continued perioperatively, the patient must be prescribed a diet that excludes foods containing high amounts of tyramine while an inpatient to avoid precipitating a hypertensive crisis  (
         <a class="graphic graphic_table graphicRef80345" href="/z/d/graphic/80345.html" rel="external">
          table 9
         </a>
         ). Intraoperative and perioperative drug interactions must be closely monitored. Specific interactions of MAO inhibitors with other medications may be determined using the
         <a class="external" href="/drug-interactions">
          drug interactions program
         </a>
         included in UpToDate.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H34">
         <span class="h2">
          Mood stabilizing agents (lithium and valproate)
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Benefit/risk
         </strong>
         –
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          Lithium
         </a>
         has a number of physiologic effects that may be important perioperatively. Lithium decreases release of neurotransmitters and may prolong the effect of neuromuscular blockers. Lithium has a narrow therapeutic index, is highly dependent upon maintained renal function for clearance, and is subject to drug interactions with diuretics, NSAIDs, angiotensin-converting enzyme (ACE) inhibitors, and serotoninergic drugs (eg,
         <a class="drug drug_general" data-topicid="9608" href="/z/d/drug information/9608.html" rel="external">
          meperidine
         </a>
         ,
         <a class="drug drug_general" data-topicid="9636" href="/z/d/drug information/9636.html" rel="external">
          methylene blue
         </a>
         ,
         <a class="drug drug_general" data-topicid="10010" href="/z/d/drug information/10010.html" rel="external">
          tramadol
         </a>
         ). Chronic lithium use has a multitude of effects on the thyroid. (See
         <a class="medical medical_review" href="/z/d/html/7843.html" rel="external">
          "Lithium and the thyroid"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/15317.html" rel="external">
          "Bipolar disorder in adults and lithium: Pharmacology, administration, and management of adverse effects", section on 'Managing lithium adverse effects'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In addition, arginine
         <a class="drug drug_general" data-topicid="10039" href="/z/d/drug information/10039.html" rel="external">
          vasopressin
         </a>
         resistance (previously called nephrogenic diabetes insipidus) has been described in up to 20 percent of patients taking
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          lithium
         </a>
         . Patients who have impaired renal concentrating ability maintain euvolemia and a normal serum sodium through polydipsia. Access to free water may be impaired during the perioperative period and lead to volume depletion and hypernatremia. (See
         <a class="medical medical_review" href="/z/d/html/2358.html" rel="external">
          "Renal toxicity of lithium"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Valproate (
         <a class="drug drug_general" data-topicid="10035" href="/z/d/drug information/10035.html" rel="external">
          valproic acid
         </a>
         ) is another mood stabilizer used in patients with bipolar disorder. Valproate drug interactions include NSAIDs and some antibiotics. There are no reports demonstrating problems in patients continuing valproic acid perioperatively.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Continue/discontinue
         </strong>
         –
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          Lithium
         </a>
         and
         <a class="drug drug_general" data-topicid="10035" href="/z/d/drug information/10035.html" rel="external">
          valproate
         </a>
         are used for treatment of serious mental illness. We therefore recommend continuation of lithium perioperatively with increased attention to fluid and electrolyte monitoring and a low threshold to check thyroid function tests before surgery.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         We recommend that
         <a class="drug drug_general" data-topicid="10035" href="/z/d/drug information/10035.html" rel="external">
          valproic acid
         </a>
         be continued.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Serum levels of
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          lithium
         </a>
         and
         <a class="drug drug_general" data-topicid="10035" href="/z/d/drug information/10035.html" rel="external">
          valproate
         </a>
         should be monitored regularly. Serum lithium levels are affected by medications that affect sodium and fluid balance. (See
         <a class="medical medical_review" href="/z/d/html/15317.html" rel="external">
          "Bipolar disorder in adults and lithium: Pharmacology, administration, and management of adverse effects", section on 'Laboratory tests and monitoring'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/679.html" rel="external">
          "Bipolar mania and hypomania in adults: Choosing pharmacotherapy", section on 'Valproate or divalproex'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Formulations/alternatives
         </strong>
         –
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          Lithium
         </a>
         must be temporarily discontinued in patients who cannot take oral medications since no parenteral substitution is available. Restarting enteral lithium (with close monitoring of electrolytes) within 24 hours postoperatively should avoid the need for alternative pharmacologic coverage.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <a class="drug drug_general" data-topicid="10035" href="/z/d/drug information/10035.html" rel="external">
          Valproate
         </a>
         sodium is available as a parenteral form. Valproate or second-generation antipsychotics (eg,
         <a class="drug drug_general" data-topicid="9868" href="/z/d/drug information/9868.html" rel="external">
          risperidone
         </a>
         ,
         <a class="drug drug_general" data-topicid="8786" href="/z/d/drug information/8786.html" rel="external">
          aripiprazole
         </a>
         ,
         <a class="drug drug_general" data-topicid="9716" href="/z/d/drug information/9716.html" rel="external">
          olanzapine
         </a>
         , or
         <a class="drug drug_general" data-topicid="10040" href="/z/d/drug information/10040.html" rel="external">
          ziprasidone
         </a>
         ) may be used in lieu of
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          lithium
         </a>
         for patients who cannot take oral medications. (See
         <a class="medical medical_review" href="/z/d/html/680.html" rel="external">
          "Bipolar disorder in adults: Choosing maintenance treatment"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H35">
         <span class="h2">
          Antipsychotics
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Benefit/risk
         </strong>
         – Antipsychotics are effective in controlling psychoses that may become problematic in the perioperative period in patients with underlying psychiatric illness. However, findings from a large observational study indicate that use of antipsychotics, both typical and atypical, is associated with an increased risk for sudden death [
         <a href="#rid127">
          127
         </a>
         ]. Both typical and atypical antipsychotics may prolong the QT interval and cause arrhythmia, particularly when coadministered with volatile anesthetic agents or drugs such as
         <a class="drug drug_general" data-topicid="9418" href="/z/d/drug information/9418.html" rel="external">
          erythromycin
         </a>
         , quinolones,
         <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">
          amiodarone
         </a>
         , and
         <a class="drug drug_general" data-topicid="9941" href="/z/d/drug information/9941.html" rel="external">
          sotalol
         </a>
         . (See
         <a class="medical medical_review" href="/z/d/html/14773.html" rel="external">
          "First-generation antipsychotic medications: Pharmacology, administration, and comparative side effects"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/14776.html" rel="external">
          "Second-generation antipsychotic medications: Pharmacology, administration, and side effects"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1043.html" rel="external">
          "Acquired long QT syndrome: Definitions, pathophysiology, and causes"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In a randomized trial of 495 patients at risk for delirium undergoing joint replacement surgery,
         <a class="drug drug_general" data-topicid="9716" href="/z/d/drug information/9716.html" rel="external">
          olanzapine
         </a>
         versus placebo was administered to prevent delirium [
         <a href="#rid128">
          128
         </a>
         ]. The incidence of delirium decreased from 40 to 1 percent, although those who experienced delirium in the olanzapine group had more severe and longer-lasting delirium. Resource use during hospitalization (sitters, consultations) did not decrease. More patients in the olanzapine arm were discharged to home versus rehabilitation facilities. A randomized controlled trial in intensive care unit (ICU) patients in China showed that the administration of prophylactic
         <a class="drug drug_general" data-topicid="8516" href="/z/d/drug information/8516.html" rel="external">
          haloperidol
         </a>
         for seven days after noncardiac surgery significantly decreased the incidence of postoperative delirium, while the mean time to onset of delirium and the mean number of delirium-free days was significantly longer [
         <a href="#rid129">
          129
         </a>
         ]. ICU stay was significantly shorter. No difference in mortality or drug-related side effects was noted. Further studies are needed prior to widespread use of perioperative antipsychotics for delirium prevention.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Continue/discontinue
         </strong>
         – Antipsychotics should be used cautiously in patients at risk for exacerbation of psychoses. These agents should be withheld in patients whose baseline or follow-up electrocardiogram (ECG) demonstrates prolongation of the QT interval. Shorter-acting and low-dose antipsychotics should be considered, and complete discontinuation may be preferable after consultation with a psychiatrist. The half-life of antipsychotics varies widely. Rarely, withdrawal symptoms (eg, nausea, vomiting, insomnia) or rebound psychoses can occur following abrupt discontinuation.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Antipsychotics may potentiate sedative and hypotensive effects of anesthetics and opiate analgesics. They variably cause extrapyramidal side effects and, rarely, neuroleptic malignant syndrome (see
         <a class="medical medical_review" href="/z/d/html/4829.html" rel="external">
          "Neuroleptic malignant syndrome"
         </a>
         ) Several antipsychotics undergo or inhibit CYP2D6 and/or CYP3A4 drug metabolism and thereby can interact with other drugs used perioperatively (eg, antibiotics,
         <a class="drug drug_general" data-topicid="9650" href="/z/d/drug information/9650.html" rel="external">
          midazolam
         </a>
         ,
         <a class="drug drug_general" data-topicid="8588" href="/z/d/drug information/8588.html" rel="external">
          ketamine
         </a>
         ). Parenteral administration of antipsychotics seems to increase the perioperative risk of additive sedation, hypotension, or QTc prolongation with other drugs.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Formulations/alternatives
         </strong>
         – Many typical antipsychotics are available in short-acting intramuscular form, with the high-potency agents more likely to cause extrapyramidal effects and low-potency agents more likely to cause hypotension and sedation. Both
         <a class="drug drug_general" data-topicid="8516" href="/z/d/drug information/8516.html" rel="external">
          haloperidol
         </a>
         decanoate and
         <a class="drug drug_general" data-topicid="8467" href="/z/d/drug information/8467.html" rel="external">
          fluphenazine
         </a>
         decanoate are long-acting depot preparations that are given monthly and every two weeks, respectively. Haloperidol, although not approved by the US Food and Drug Administration (FDA) for intravenous use, is the most common intravenous antipsychotic used in the hospital setting. It has minimal hemodynamic or extrapyramidal side effects [
         <a href="#rid130">
          130
         </a>
         ] and progressive dosing guidelines have been published for the agitated patient [
         <a href="#rid131">
          131,132
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Several parenteral formulations of atypical antipsychotics are available, including short-acting forms of intramuscular
         <a class="drug drug_general" data-topicid="9716" href="/z/d/drug information/9716.html" rel="external">
          olanzapine
         </a>
         and
         <a class="drug drug_general" data-topicid="10040" href="/z/d/drug information/10040.html" rel="external">
          ziprasidone
         </a>
         , and a long-acting
         <a class="drug drug_general" data-topicid="9868" href="/z/d/drug information/9868.html" rel="external">
          risperidone
         </a>
         preparation used as a maintenance treatment. Olanzapine and risperidone have an oral dissolvable tablet formulation that can be used for the patient in need of an antipsychotic who cannot take oral medication  (
         <a class="graphic graphic_table graphicRef60624" href="/z/d/graphic/60624.html" rel="external">
          table 10
         </a>
         ) [
         <a href="#rid133">
          133
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H36">
         <span class="h2">
          Antianxiety agents
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Benefit/risk
         </strong>
         – Abrupt withdrawal of chronic benzodiazepines can lead to an excitatory state with hypertension, agitation, delirium, and seizures. Many of these agents have active metabolites, and withdrawal can occur several days to weeks after discontinuation. Withdrawal symptoms can occur in less than 24 hours following abrupt discontinuation of chronic
         <a class="drug drug_general" data-topicid="8453" href="/z/d/drug information/8453.html" rel="external">
          alprazolam
         </a>
         use. Conversion to an extended release preparation of alprazolam prior to surgery may be useful for delaying the need for postoperative re-dosing.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In one center, anxiolytic medication use on admission (present in 16 percent of 1846 patients) was associated with a greater risk of postoperative complications after noncardiac surgery (OR = 1.72, 95% CI: 1.08-2.73) [
         <a href="#rid134">
          134
         </a>
         ]. However, it is uncertain as to whether the risk was attributable to medication or to the presence of anxiety.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Benzodiazepines are commonly used short-term to relieve preoperative anxiety and are generally safe, with proper monitoring, in the perioperative period. Additive sedation or increased tolerance to perioperative anesthetic and sedative agents may be observed.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <a class="drug drug_general" data-topicid="9172" href="/z/d/drug information/9172.html" rel="external">
          Buspirone
         </a>
         is felt to be safe in the perioperative period; it has been reported to reduce the shivering threshold intraoperatively in conjunction with
         <a class="drug drug_general" data-topicid="8897" href="/z/d/drug information/8897.html" rel="external">
          dexmedetomidine
         </a>
         with minimal sedation and no respiratory depression [
         <a href="#rid135">
          135
         </a>
         ]. It has a slow onset of effect (ie, weeks) and does not prevent withdrawal reactions due to discontinuation of benzodiazepines. Due to its serotoninergic effect, its use with
         <a class="drug drug_general" data-topicid="9608" href="/z/d/drug information/9608.html" rel="external">
          meperidine
         </a>
         and
         <a class="drug drug_general" data-topicid="10010" href="/z/d/drug information/10010.html" rel="external">
          tramadol
         </a>
         is not recommended.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <strong>
          Continue/discontinue
         </strong>
         – We recommend that benzodiazepines or
         <a class="drug drug_general" data-topicid="9172" href="/z/d/drug information/9172.html" rel="external">
          buspirone
         </a>
         used chronically for antianxiety or sedative effects be continued perioperatively.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Formulations/alternatives
         </strong>
         – Parenteral forms of benzodiazepines are available, including
         <a class="drug drug_general" data-topicid="9345" href="/z/d/drug information/9345.html" rel="external">
          diazepam
         </a>
         and
         <a class="drug drug_general" data-topicid="9573" href="/z/d/drug information/9573.html" rel="external">
          lorazepam
         </a>
         .
         <a class="drug drug_general" data-topicid="9172" href="/z/d/drug information/9172.html" rel="external">
          Buspirone
         </a>
         is only available in oral formulation; parenteral benzodiazepines can be substituted if the patient cannot take oral medications and anxiety is a significant problem. Intravenous administration can cause blood pressure lability.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H37">
         <span class="h2">
          Psychostimulants
         </span>
         <span class="headingEndMark">
          —
         </span>
         Psychostimulant medications, used in the treatment of attention deficit hyperactivity disorder, may increase risk for hypertension and arrhythmias, lower the seizure threshold, and interact with medications that could be needed in the perioperative period (eg, vasopressors). There is a risk of sudden blood pressure increase when halogenated anesthetics are used in conjunction with
         <a class="drug drug_general" data-topicid="9638" href="/z/d/drug information/9638.html" rel="external">
          methylphenidate
         </a>
         , and, per drug labeling, the stimulant should be withheld on the day of surgery.
        </p>
        <p>
         A case series report of eight patients found no adverse effects when amphetamines were continued on the day of surgery [
         <a href="#rid136">
          136
         </a>
         ]. However, none of the patients required vasopressor support.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Benefit/risk
         </strong>
         – Psychostimulants are not associated with adverse effects when discontinued in the non-abusing patient. Patients generally do not need to be concerned about alertness on the day of surgery.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Continue/discontinue
         </strong>
         – Data are limited but risks are low of temporarily discontinuing psychostimulant medications. We recommend they be withheld on the day of surgery and resumed when the patient is stable.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H38">
         <span class="h1">
          CHRONIC OPIOID THERAPY
         </span>
         <span class="headingEndMark">
          —
         </span>
         Peri- and postoperative pain management in opioid dependent patients (including those taking
         <a class="drug drug_general" data-topicid="9170" href="/z/d/drug information/9170.html" rel="external">
          buprenorphine
         </a>
         and
         <a class="drug drug_general" data-topicid="9623" href="/z/d/drug information/9623.html" rel="external">
          methadone
         </a>
         ) are discussed elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/83726.html" rel="external">
          "Management of acute pain in the patient chronically using opioids for non-cancer pain"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/121628.html" rel="external">
          "Management of acute pain in adults with opioid use disorder"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H274988211">
         <span class="h1">
          NALTREXONE
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Benefit/risk
         </strong>
         –
         <a class="drug drug_general" data-topicid="9679" href="/z/d/drug information/9679.html" rel="external">
          Naltrexone
         </a>
         is a derivative of
         <a class="drug drug_general" data-topicid="9733" href="/z/d/drug information/9733.html" rel="external">
          oxymorphone
         </a>
         that acts as a competitive antagonist at opioid receptor sites, showing the highest affinity for mu receptors. It decreases cravings and helps maintain abstinence in opioid addicted patients and is also used for the treatment of alcoholism [
         <a href="#rid137">
          137
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/108891.html" rel="external">
          "Alcohol use disorder: Treatment overview", section on 'Medication strategies'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7803.html" rel="external">
          "Opioid use disorder: Pharmacologic management", section on 'Naltrexone: Opioid antagonist'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         As with
         <a class="drug drug_general" data-topicid="9170" href="/z/d/drug information/9170.html" rel="external">
          buprenorphine
         </a>
         , chronic
         <a class="drug drug_general" data-topicid="9679" href="/z/d/drug information/9679.html" rel="external">
          naltrexone
         </a>
         use may increase central nervous system (CNS) opioid receptor concentration, potentially resulting in a transient exaggerated response to agonists in an acute pain situation.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Continue/discontinue
         </strong>
         –
         <a class="drug drug_general" data-topicid="9679" href="/z/d/drug information/9679.html" rel="external">
          Naltrexone
         </a>
         should be discontinued (or the intramuscular dose held) in anticipation of surgery, and a multimodal approach to pain management should be implemented, including the use of local anesthetics with or without sedation, nonsteroidal antiinflammatory drugs (NSAIDs),
         <a class="drug drug_general" data-topicid="9242" href="/z/d/drug information/9242.html" rel="external">
          acetaminophen
         </a>
         , corticosteroids, tricyclic antidepressants, or nerve stabilizers such as
         <a class="drug drug_general" data-topicid="8483" href="/z/d/drug information/8483.html" rel="external">
          gabapentin
         </a>
         . Opioids should be used for acute pain, and agents with a higher affinity for the mu receptor (such as
         <a class="drug drug_general" data-topicid="9788" href="/z/d/drug information/9788.html" rel="external">
          morphine
         </a>
         ,
         <a class="drug drug_general" data-topicid="8441" href="/z/d/drug information/8441.html" rel="external">
          fentanyl
         </a>
         , or
         <a class="drug drug_general" data-topicid="8538" href="/z/d/drug information/8538.html" rel="external">
          hydromorphone
         </a>
         ) are recommended. In addition, a "reverse ladder" approach has been suggested to de-escalate opioid agonist therapy in the postoperative period, utilizing nonopioid alternatives for pain control in conjunction with resumption of the antagonist agent [
         <a href="#rid138">
          138
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Formulations/alternatives
         </strong>
         –
         <a class="drug drug_general" data-topicid="9679" href="/z/d/drug information/9679.html" rel="external">
          Naltrexone
         </a>
         is available in both intramuscular and oral form.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H39">
         <span class="h1">
          NEUROLOGIC AGENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The drugs taken by patients with neurologic disease around the time of surgery are discussed in detail separately (See
         <a class="medical medical_review" href="/z/d/html/4827.html" rel="external">
          "Perioperative care of the surgical patient with neurologic disease"
         </a>
         .).
        </p>
        <p class="headingAnchor" id="H42">
         <span class="h1">
          RHEUMATOLOGIC AGENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Perioperative medication management of patients with rheumatic diseases is discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/1826.html" rel="external">
          "Preoperative evaluation and perioperative management of patients with rheumatic diseases"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H44">
         <span class="h1">
          GOUT THERAPY
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Benefit/risk
         </strong>
         – Surgery is known to precipitate acute gouty arthropathy [
         <a href="#rid139">
          139
         </a>
         ]. The optimal management strategy for patients who are maintained on chronic hypouricemic therapy or
         <a class="drug drug_general" data-topicid="9293" href="/z/d/drug information/9293.html" rel="external">
          colchicine
         </a>
         in the perioperative period is unknown. Colchicine has a narrow therapeutic index and can cause muscle weakness and polyneuropathy in the setting of renal impairment or drug interactions [
         <a href="#rid140">
          140
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Continue/discontinue
         </strong>
         – We recommend that
         <a class="drug drug_general" data-topicid="9293" href="/z/d/drug information/9293.html" rel="external">
          colchicine
         </a>
         be held on the morning of surgery and resumed when the patient is able to tolerate oral medications.
         <a class="drug drug_general" data-topicid="8439" href="/z/d/drug information/8439.html" rel="external">
          Allopurinol
         </a>
         can be continued.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Formulations/alternatives
         </strong>
         – There are no parenteral substitutions for
         <a class="drug drug_general" data-topicid="8439" href="/z/d/drug information/8439.html" rel="external">
          allopurinol
         </a>
         or
         <a class="drug drug_general" data-topicid="9812" href="/z/d/drug information/9812.html" rel="external">
          probenecid
         </a>
         . Parenteral
         <a class="drug drug_general" data-topicid="9293" href="/z/d/drug information/9293.html" rel="external">
          colchicine
         </a>
         is no longer available in the United States; it can cause myelotoxicity, as well as significant skin necrosis if infiltration occurs [
         <a href="#rid141">
          141
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Should an acute gouty flare occur in a postoperative patient unable to tolerate oral medications, intraarticular steroids or systemic steroids can be used. (See
         <a class="medical medical_review" href="/z/d/html/1666.html" rel="external">
          "Treatment of gout flares"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H45">
         <span class="h1">
          MEDICATIONS FOR BENIGN PROSTATIC HYPERTROPHY
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Benefit/risk
         </strong>
         – Some patients treated with alpha-1-antagonists (eg,
         <a class="drug drug_general" data-topicid="9975" href="/z/d/drug information/9975.html" rel="external">
          terazosin
         </a>
         ,
         <a class="drug drug_general" data-topicid="9389" href="/z/d/drug information/9389.html" rel="external">
          doxazosin
         </a>
         ,
         <a class="drug drug_general" data-topicid="9654" href="/z/d/drug information/9654.html" rel="external">
          tamsulosin
         </a>
         ,
         <a class="drug drug_general" data-topicid="9105" href="/z/d/drug information/9105.html" rel="external">
          alfuzosin
         </a>
         ) have developed intraoperative floppy iris syndrome (IFIS), a condition involving intractable intraoperative iris prolapse with cataract surgery [
         <a href="#rid142">
          142-144
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Continue/discontinue
         </strong>
         – Patients should be asked about use of alpha-1-antagonists during the preoperative evaluation. It is not known if discontinuing alpha-1-antagonists reduces the risk of IFIS; clinical impression is that the drug effect is long-lasting (weeks, months, or years), and most eye surgeons do not insist that these agents be discontinued. Various operative regimens can reduce the occurrence of IFIS. It is important to make sure the surgeon is aware if the patient was receiving such a medication. Otherwise, these drugs should be continued as they may be beneficial in preventing postoperative urinary retention. (See
         <a class="medical medical_review" href="/z/d/html/6904.html" rel="external">
          "Cataract in adults"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H46">
         <span class="h1">
          HERBAL MEDICATIONS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Herbal medications, used frequently, may have effects that could be deleterious in the perioperative period, including clotting abnormalities and interactions with anesthetics [
         <a href="#rid145">
          145
         </a>
         ]. Clinicians should specifically inquire about herbal medication use in presurgical patients, as patients often do not readily disclose use.
        </p>
        <p>
         There is no evidence that herbal medications improve surgical outcomes, and there are theoretic reasons that these agents may increase perioperative morbidity. For simplicity and because the purity and nature of some herbal medications is unclear, we recommend stopping herbal agents at least one week before surgery. (See
         <a class="medical medical_review" href="/z/d/html/1392.html" rel="external">
          "Overview of herbal medicine and dietary supplements"
         </a>
         .)
        </p>
        <p>
         A review that examined eight commonly used herbal remedies found the following [
         <a href="#rid146">
          146
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Ephedra (ma huang) may increase the risk of heart attack and stroke and should be discontinued at least 24 hours prior to surgery.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Garlic may increase bleeding risk and should be discontinued at least seven days prior to surgery.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Ginkgo may increase bleeding risk and should be discontinued at least 36 hours prior to surgery.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Ginseng lowers blood sugar and may increase bleeding risk and should be discontinued at least seven days prior to surgery.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Kava may increase the sedative effect of anesthetics and should be discontinued at least 24 hours prior to surgery. An association between kava use and fatal hepatotoxicity has been reported. (See
         <a class="medical medical_review" href="/z/d/html/3618.html" rel="external">
          "Hepatotoxicity due to herbal medications and dietary supplements"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         St. John's wort may diminish the effects of several drugs by induction of cytochrome P450 enzymes and should be discontinued at least five days prior to surgery.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Valerian may increase the sedative effect of anesthetics and is associated with benzodiazepine-like withdrawal. There are no data on preoperative discontinuation. Ideally it is tapered weeks before surgery; if not, withdrawal is treated with benzodiazepines.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Echinacea is associated with allergic reactions and immune stimulation. There are no data on preoperative discontinuation.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H47">
         <span class="h1">
          ANTIRETROVIRAL AGENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The perioperative management of patients taking antiretroviral agents is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/3732.html" rel="external">
          "Surgical issues in HIV infection"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3322369543">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/126589.html" rel="external">
          "Society guideline links: Preoperative medical evaluation and risk assessment"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H48">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Principles of perioperative medication management
         </strong>
         – Clinicians must often decide if chronic medications should be continued in the perioperative period, although there are few outcome data about most medications. The following general principles inform the perioperative management of chronic medications (see
         <a class="local">
          'Introduction'
         </a>
         above and
         <a class="local">
          'Principles of medication management'
         </a>
         above):
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         A complete medication history (including all over-the-counter and herbal/complementary medications) should be obtained, and all clinicians involved in patient management should review the medication history.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Medications associated with known morbidity if withdrawn abruptly should be continued or tapered if feasible. Intravenous, transdermal, or transmucosal medicines should be substituted when absorption will be impaired because of loss of gastrointestinal function or restrictions on oral intake. Medications thought to increase the risk of anesthetic or surgical complications and not essential for the short term should be held through the perioperative period.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         The many medications administered perioperatively during a relatively short period increase the potential for drug-drug interactions.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         The metabolism and elimination of medications and their metabolites may be altered during the perioperative period.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         The majority of medications can be resumed once the patient is able to tolerate oral intake, with the exception of medications that impact the bleeding or thromboembolic risk.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Specific recommendations by medication category
         </strong>
         – Recommendations for medication management by medication/category/class are reviewed:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Cardiovascular agents  (
         <a class="graphic graphic_table graphicRef62659" href="/z/d/graphic/62659.html" rel="external">
          table 1
         </a>
         ) (see
         <a class="local">
          'Cardiovascular medications'
         </a>
         above)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Gastrointestinal agents  (
         <a class="graphic graphic_table graphicRef56778" href="/z/d/graphic/56778.html" rel="external">
          table 2
         </a>
         ) (see
         <a class="local">
          'Gastrointestinal agents'
         </a>
         above)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Pulmonary agents  (
         <a class="graphic graphic_table graphicRef56778" href="/z/d/graphic/56778.html" rel="external">
          table 2
         </a>
         ) (see
         <a class="local">
          'Pulmonary agents'
         </a>
         above)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Endocrine agents  (
         <a class="graphic graphic_table graphicRef77781" href="/z/d/graphic/77781.html" rel="external">
          table 3
         </a>
         ) (see
         <a class="local">
          'Endocrine agents'
         </a>
         above)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Agents affecting hemostasis  (
         <a class="graphic graphic_table graphicRef68515" href="/z/d/graphic/68515.html" rel="external">
          table 6
         </a>
         ) (see
         <a class="local">
          'Medications affecting hemostasis'
         </a>
         above)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Psychotropic agents  (
         <a class="graphic graphic_table graphicRef66948" href="/z/d/graphic/66948.html" rel="external">
          table 7
         </a>
         ) (see
         <a class="local">
          'Psychotropic agents'
         </a>
         above)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Chronic opioid therapy (see
         <a class="medical medical_review" href="/z/d/html/83726.html" rel="external">
          "Management of acute pain in the patient chronically using opioids for non-cancer pain"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/121628.html" rel="external">
          "Management of acute pain in adults with opioid use disorder"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <a class="drug drug_general" data-topicid="9679" href="/z/d/drug information/9679.html" rel="external">
          Naltrexone
         </a>
         (see
         <a class="local">
          'Naltrexone'
         </a>
         above)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Neurologic agents (see
         <a class="medical medical_review" href="/z/d/html/4827.html" rel="external">
          "Perioperative care of the surgical patient with neurologic disease"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Rheumatologic agents (see
         <a class="medical medical_review" href="/z/d/html/1826.html" rel="external">
          "Preoperative evaluation and perioperative management of patients with rheumatic diseases"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Gout therapy (see
         <a class="local">
          'Gout therapy'
         </a>
         above)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Medications for benign prostatic hypertrophy (see
         <a class="local">
          'Medications for benign prostatic hypertrophy'
         </a>
         above)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Herbal medications (see
         <a class="local">
          'Herbal medications'
         </a>
         above)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Antiretroviral agents (see
         <a class="medical medical_review" href="/z/d/html/3732.html" rel="external">
          "Surgical issues in HIV infection"
         </a>
         )
        </p>
        <p>
        </p>
        <p>
         <strong>
          ACKNOWLEDGMENT
         </strong>
         — The UpToDate editorial staff acknowledges David Macpherson, MD, who contributed to an earlier version of this topic review.
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Kennedy JM, van Rij AM, Spears GF, et al. Polypharmacy in a general surgical unit and consequences of drug withdrawal. Br J Clin Pharmacol 2000; 49:353.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kroenke K, Gooby-Toedt D, Jackson JL. Chronic medications in the perioperative period. South Med J 1998; 91:358.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Spell NO 3rd. Stopping and restarting medications in the perioperative period. Med Clin North Am 2001; 85:1117.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Smith MS, Muir H, Hall R. Perioperative management of drug therapy, clinical considerations. Drugs 1996; 51:238.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Clay BJ, Halasyamani L, Stucky ER, et al. Results of a medication reconciliation survey from the 2006 Society of Hospital Medicine national meeting. J Hosp Med 2008; 3:465.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pass SE, Simpson RW. Discontinuation and reinstitution of medications during the perioperative period. Am J Health Syst Pharm 2004; 61:899.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Marcucci M, Painter TW, Conen D, et al. Hypotension-Avoidance Versus Hypertension-Avoidance Strategies in Noncardiac Surgery : An International Randomized Controlled Trial. Ann Intern Med 2023; 176:605.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shammash JB, Trost JC, Gold JM, et al. Perioperative beta-blocker withdrawal and mortality in vascular surgical patients. Am Heart J 2001; 141:148.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wallace AW, Au S, Cason BA. Association of the pattern of use of perioperative β-blockade and postoperative mortality. Anesthesiology 2010; 113:794.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kertai MD, Cooter M, Pollard RJ, et al. Is Compliance With Surgical Care Improvement Project Cardiac (SCIP-Card-2) Measures for Perioperative β-Blockers Associated With Reduced Incidence of Mortality and Cardiovascular-Related Critical Quality Indicators After Noncardiac Surgery? Anesth Analg 2018; 126:1829.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, American Society of Echocardiography, American Society of Nuclear Cardiology, et al. 2009 ACCF/AHA focused update on perioperative beta blockade. J Am Coll Cardiol 2009; 54:2102.
          </a>
         </li>
         <li class="breakAll">
          Hoffman BB. Therapy of hypertension. In: Goodman and Gilman's The Pharmacological Basis of Therapeutics, 11th ed, Brunton LB, Lazo JS, Parker KL (Eds), McGraw-Hill, New York 2006.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Berggren H, Ekroth R, Herlitz J, et al. Myocardial protective effect of maintained beta-blockade in aorto-coronary bypass surgery. Scand J Thorac Cardiovasc Surg 1983; 17:29.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pontén J, Biber B, Henriksson BA, et al. beta-Receptor blockade and neurolept anaesthesia. Withdrawal vs continuation of long-term therapy in gall-bladder and carotid artery surgery. Acta Anaesthesiol Scand 1982; 26:576.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mashour GA, Sharifpour M, Freundlich RE, et al. Perioperative metoprolol and risk of stroke after noncardiac surgery. Anesthesiology 2013; 119:1340.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ashes C, Judelman S, Wijeysundera DN, et al. Selective β1-antagonism with bisoprolol is associated with fewer postoperative strokes than atenolol or metoprolol: a single-center cohort study of 44,092 consecutive patients. Anesthesiology 2013; 119:777.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dai N, Xu D, Zhang J, et al. Different β-blockers and initiation time in patients undergoing noncardiac surgery: a meta-analysis. Am J Med Sci 2014; 347:235.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wallace AW, Au S, Cason BA. Perioperative β-blockade: atenolol is associated with reduced mortality when compared to metoprolol. Anesthesiology 2011; 114:824.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           van Lier F, Schouten O, Hoeks SE, et al. Impact of prophylactic beta-blocker therapy to prevent stroke after noncardiac surgery. Am J Cardiol 2010; 105:43.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stühmeier KD, Mainzer B, Cierpka J, et al. Small, oral dose of clonidine reduces the incidence of intraoperative myocardial ischemia in patients having vascular surgery. Anesthesiology 1996; 85:706.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Oliver MF, Goldman L, Julian DG, Holme I. Effect of mivazerol on perioperative cardiac complications during non-cardiac surgery in patients with coronary heart disease: the European Mivazerol Trial (EMIT). Anesthesiology 1999; 91:951.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wallace AW, Galindez D, Salahieh A, et al. Effect of clonidine on cardiovascular morbidity and mortality after noncardiac surgery. Anesthesiology 2004; 101:284.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Devereaux PJ, Sessler DI, Leslie K, et al. Clonidine in patients undergoing noncardiac surgery. N Engl J Med 2014; 370:1504.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Garg AX, Kurz A, Sessler DI, et al. Aspirin and clonidine in non-cardiac surgery: acute kidney injury substudy protocol of the Perioperative Ischaemic Evaluation (POISE) 2 randomised controlled trial. BMJ Open 2014; 4:e004886.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lilja M, Jounela AJ, Juustila H. Withdrawal syndromes and the cessation of antihypertensive therapy. Arch Intern Med 1982; 142:839.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hart GR, Anderson RJ. Withdrawal syndromes and the cessation of antihypertensive therapy. Arch Intern Med 1981; 141:1125.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bruce DL, Croley TF, Lee JS. Preoperative clonidine withdrawal syndrome. Anesthesiology 1979; 51:90.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Metz S, Klein C, Morton N. Rebound hypertension after discontinuation of transdermal clonidine therapy. Am J Med 1987; 82:17.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Houston MC. Abrupt cessation of treatment in hypertension: consideration of clinical features, mechanisms, prevention and management of the discontinuation syndrome. Am Heart J 1981; 102:415.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ram CV, Holland OB, Fairchild C, Gomez-Sanchez CE. Withdrawal syndrome following cessation of guanabenz therapy. J Clin Pharmacol 1979; 19:148.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Colson P, Médioni P, Saussine M, et al. Hemodynamic effect of calcium channel blockade during anesthesia for coronary artery surgery. J Cardiothorac Vasc Anesth 1992; 6:424.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wijeysundera DN, Beattie WS, Rao V, et al. Calcium antagonists are associated with reduced mortality after cardiac surgery: a propensity analysis. J Thorac Cardiovasc Surg 2004; 127:755.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wijeysundera DN, Beattie WS. Calcium channel blockers for reducing cardiac morbidity after noncardiac surgery: a meta-analysis. Anesth Analg 2003; 97:634.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Reves JG, Kissin I, Lell WA, Tosone S. Calcium entry blockers: uses and implications for anesthesiologists. Anesthesiology 1982; 57:504.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Engelman RM, Hadji-Rousou I, Breyer RH, et al. Rebound vasospasm after coronary revascularization in association with calcium antagonist withdrawal. Ann Thorac Surg 1984; 37:469.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kizer JR, Kimmel SE. Epidemiologic review of the calcium channel blocker drugs. An up-to-date perspective on the proposed hazards. Arch Intern Med 2001; 161:1145.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Legault C, Furberg CD, Wagenknecht LE, et al. Nimodipine neuroprotection in cardiac valve replacement: report of an early terminated trial. Stroke 1996; 27:593.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wagenknecht LE, Furberg CD, Hammon JW, et al. Surgical bleeding: unexpected effect of a calcium antagonist. BMJ 1995; 310:776.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zuccalá G, Pahor M, Landi F, et al. Use of calcium antagonists and need for perioperative transfusion in older patients with hip fracture: observational study. BMJ 1997; 314:643.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Effects of calcium antagonists on the risks of coronary heart disease, cancer and bleeding. Ad Hoc Subcommittee of the Liaison Committee of the World Health Organisation and the International Society of Hypertension. J Hypertens 1997; 15:105.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Grodecki-DeFranco P, Steinhubl S, Taylor P, et al. Calcium antagonist use and perioperative bleeding complications: an analysis of 5,157 patients. Circulation 1996; 94(suppl):I.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Finegan BA, Hussain MD, Tam YK. Pharmacokinetics of diltiazem in patients undergoing coronary artery bypass grafting. Ther Drug Monit 1992; 14:485.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kheterpal S, Khodaparast O, Shanks A, et al. Chronic angiotensin-converting enzyme inhibitor or angiotensin receptor blocker therapy combined with diuretic therapy is associated with increased episodes of hypotension in noncardiac surgery. J Cardiothorac Vasc Anesth 2008; 22:180.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Turan A, You J, Shiba A, et al. Angiotensin converting enzyme inhibitors are not associated with respiratory complications or mortality after noncardiac surgery. Anesth Analg 2012; 114:552.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shiffermiller JF, Monson BJ, Vokoun CW, et al. Prospective Randomized Evaluation of Preoperative Angiotensin-Converting Enzyme Inhibition (PREOP-ACEI). J Hosp Med 2018; 13:661.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hollmann C, Fernandes NL, Biccard BM. A Systematic Review of Outcomes Associated With Withholding or Continuing Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers Before Noncardiac Surgery. Anesth Analg 2018; 127:678.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Roshanov PS, Rochwerg B, Patel A, et al. Withholding versus Continuing Angiotensin-converting Enzyme Inhibitors or Angiotensin II Receptor Blockers before Noncardiac Surgery: An Analysis of the Vascular events In noncardiac Surgery patIents cOhort evaluatioN Prospective Cohort. Anesthesiology 2017; 126:16.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ackland GL, Patel A, Abbott TEF, et al. Discontinuation vs. continuation of renin-angiotensin system inhibition before non-cardiac surgery: the SPACE trial. Eur Heart J 2023.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pigott DW, Nagle C, Allman K, et al. Effect of omitting regular ACE inhibitor medication before cardiac surgery on haemodynamic variables and vasoactive drug requirements. Br J Anaesth 1999; 83:715.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hasija S, Makhija N, Choudhury M, et al. Prophylactic vasopressin in patients receiving the angiotensin-converting enzyme inhibitor ramipril undergoing coronary artery bypass graft surgery. J Cardiothorac Vasc Anesth 2010; 24:230.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Drenger B, Fontes ML, Miao Y, et al. Patterns of use of perioperative angiotensin-converting enzyme inhibitors in coronary artery bypass graft surgery with cardiopulmonary bypass: effects on in-hospital morbidity and mortality. Circulation 2012; 126:261.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Benedetto U, Melina G, Capuano F, et al. Preoperative angiotensin-converting enzyme inhibitors protect myocardium from ischemia during coronary artery bypass graft surgery. J Cardiovasc Med (Hagerstown) 2008; 9:1098.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Benedetto U, Sciarretta S, Roscitano A, et al. Preoperative Angiotensin-converting enzyme inhibitors and acute kidney injury after coronary artery bypass grafting. Ann Thorac Surg 2008; 86:1160.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Arora P, Rajagopalam S, Ranjan R, et al. Preoperative use of angiotensin-converting enzyme inhibitors/angiotensin receptor blockers is associated with increased risk for acute kidney injury after cardiovascular surgery. Clin J Am Soc Nephrol 2008; 3:1266.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cheungpasitporn W, Thongprayoon C, Srivali N, et al. Preoperative renin-angiotensin system inhibitors use linked to reduced acute kidney injury: a systematic review and meta-analysis. Nephrol Dial Transplant 2015; 30:978.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shah M, Jain AK, Brunelli SM, et al. Association between angiotensin converting enzyme inhibitor or angiotensin receptor blocker use prior to major elective surgery and the risk of acute dialysis. BMC Nephrol 2014; 15:53.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nielson E, Hennrikus E, Lehman E, Mets B. Angiotensin axis blockade, hypotension, and acute kidney injury in elective major orthopedic surgery. J Hosp Med 2014; 9:283.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lee SM, Takemoto S, Wallace AW. Association between Withholding Angiotensin Receptor Blockers in the Early Postoperative Period and 30-day Mortality: A Cohort Study of the Veterans Affairs Healthcare System. Anesthesiology 2015; 123:288.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mudumbai SC, Takemoto S, Cason BA, et al. Thirty-day mortality risk associated with the postoperative nonresumption of angiotensin-converting enzyme inhibitors: a retrospective study of the Veterans Affairs Healthcare System. J Hosp Med 2014; 9:289.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fleisher LA, Fleischmann KE, Auerbach AD, et al. 2014 ACC/AHA guideline on perioperative cardiovascular evaluation and management of patients undergoing noncardiac surgery: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2014; 130:e278.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kristensen SD, Knuuti J, Saraste A, et al. 2014 ESC/ESA Guidelines on non-cardiac surgery: cardiovascular assessment and management: The Joint Task Force on non-cardiac surgery: cardiovascular assessment and management of the European Society of Cardiology (ESC) and the European Society of Anaesthesiology (ESA). Eur Heart J 2014; 35:2383.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Duceppe E, Parlow J, MacDonald P, et al. Canadian Cardiovascular Society Guidelines on Perioperative Cardiac Risk Assessment and Management for Patients Who Undergo Noncardiac Surgery. Can J Cardiol 2017; 33:17.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hirsch IA, Tomlinson DL, Slogoff S, Keats AS. The overstated risk of preoperative hypokalemia. Anesth Analg 1988; 67:131.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nally BR, Dunbar SB, Zellinger M, Davis A. Supraventricular tachycardia after coronary artery bypass grafting surgery and fluid and electrolyte variables. Heart Lung 1996; 25:31.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Khan NA, Campbell NR, Frost SD, et al. Risk of intraoperative hypotension with loop diuretics: a randomized controlled trial. Am J Med 2010; 123:1059.e1.
          </a>
         </li>
         <li class="breakAll">
          Roizen MF. etic implications of concurrent diseases. In: Anesthesia, Miller RD (Ed), Churchill Livingstone, Philadelphia 2000. p.903.
         </li>
         <li class="breakAll">
          Farmer JA, Gotto AM. Dyslipidemia and other risk factors for coronary artery disease. In: A Textbook of Cardiovascular Medicine, Braunwald E (Ed), W.B. Saunders, Philadelphia 1997. p.1126.
         </li>
         <li class="breakAll">
          Physicians Desk Reference, Medical Economics Company, Montvale, NJ 2000.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hamilton-Craig I. Statin-associated myopathy. Med J Aust 2001; 175:486.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shek A, Ferrill MJ. Statin-fibrate combination therapy. Ann Pharmacother 2001; 35:908.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hollenberg M, Mangano DT, Browner WS, et al. Predictors of postoperative myocardial ischemia in patients undergoing noncardiac surgery. The Study of Perioperative Ischemia Research Group. JAMA 1992; 268:205.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Polanczyk CA, Goldman L, Marcantonio ER, et al. Supraventricular arrhythmia in patients having noncardiac surgery: clinical correlates and effect on length of stay. Ann Intern Med 1998; 129:279.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nishina K, Mikawa K, Takao Y, et al. A comparison of rabeprazole, lansoprazole, and ranitidine for improving preoperative gastric fluid property in adults undergoing elective surgery. Anesth Analg 2000; 90:717.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cruickshank RH, Morrison DA, Bamber PA, Nimmo WS. Effect of i.v. omeprazole on the pH and volume of gastric contents before surgery. Br J Anaesth 1989; 63:536.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cantú TG, Korek JS. Central nervous system reactions to histamine-2 receptor blockers. Ann Intern Med 1991; 114:1027.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Su FW, Beckman DB, Yarnold PA, Grammer LC. Low incidence of complications in asthmatic patients treated with preoperative corticosteroids. Allergy Asthma Proc 2004; 25:327.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Reiss TF, Chervinsky P, Dockhorn RJ, et al. Montelukast, a once-daily leukotriene receptor antagonist, in the treatment of chronic asthma: a multicenter, randomized, double-blind trial. Montelukast Clinical Research Study Group. Arch Intern Med 1998; 158:1213.
          </a>
         </li>
         <li class="breakAll">
          American Society of Anesthesiologists Consensus-Based Guidance on Preoperative Management of Patients (Adults and Children) on Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists. American Society of Anesthesiologists, 2023. Available at: https://www.asahq.org/about-asa/newsroom/news-releases/2023/06/american-society-of-anesthesiologists-consensus-based-guidance-on-preoperative (Accessed on November 28, 2023).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Williams RG, Yardley MP. Oral contraceptive therapy and the surgical management of ENT patients: a review of current clinical practice. Clin Otolaryngol Allied Sci 1990; 15:525.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vandenbroucke JP, Rosing J, Bloemenkamp KW, et al. Oral contraceptives and the risk of venous thrombosis. N Engl J Med 2001; 344:1527.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Grady D, Wenger NK, Herrington D, et al. Postmenopausal hormone therapy increases risk for venous thromboembolic disease. The Heart and Estrogen/progestin Replacement Study. Ann Intern Med 2000; 132:689.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Miller J, Chan BK, Nelson HD. Postmenopausal estrogen replacement and risk for venous thromboembolism: a systematic review and meta-analysis for the U.S. Preventive Services Task Force. Ann Intern Med 2002; 136:680.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hurbanek JG, Jaffer AK, Morra N, et al. Postmenopausal hormone replacement and venous thromboembolism following hip and knee arthroplasty. Thromb Haemost 2004; 92:337.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Canonico M, Oger E, Plu-Bureau G, et al. Hormone therapy and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration and progestogens: the ESTHER study. Circulation 2007; 115:840.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Renoux C, Dell'Aniello S, Suissa S. Hormone replacement therapy and the risk of venous thromboembolism: a population-based study. J Thromb Haemost 2010; 8:979.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Canonico M, Fournier A, Carcaillon L, et al. Postmenopausal hormone therapy and risk of idiopathic venous thromboembolism: results from the E3N cohort study. Arterioscler Thromb Vasc Biol 2010; 30:340.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cummings SR, Eckert S, Krueger KA, et al. The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation. JAMA 1999; 281:2189.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 1998; 90:1371.
          </a>
         </li>
         <li class="breakAll">
          American Association of Oral and Maxillofacial Surgeons.Position paper: Medication-related osteonecrosis of the jaw - 2014 update http://www.aaoms.org/docs/position_papers/mronj_position_paper.pdf?pdf=MRONJ-Position-Paper (Accessed on October 01, 2014).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Connelly CS, Panush RS. Should nonsteroidal anti-inflammatory drugs be stopped before elective surgery? Arch Intern Med 1991; 151:1963.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sethi GK, Copeland JG, Goldman S, et al. Implications of preoperative administration of aspirin in patients undergoing coronary artery bypass grafting. Department of Veterans Affairs Cooperative Study on Antiplatelet Therapy. J Am Coll Cardiol 1990; 15:15.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bashein G, Nessly ML, Rice AL, et al. Preoperative aspirin therapy and reoperation for bleeding after coronary artery bypass surgery. Arch Intern Med 1991; 151:89.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Scher KS. Unplanned reoperation for bleeding. Am Surg 1996; 62:52.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Watson CJ, Deane AM, Doyle PT, Bullock KN. Identifiable factors in post-prostatectomy haemorrhage: the role of aspirin. Br J Urol 1990; 66:85.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Taggart DP, Siddiqui A, Wheatley DJ. Low-dose preoperative aspirin therapy, postoperative blood loss, and transfusion requirements. Ann Thorac Surg 1990; 50:424.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mangano DT, Multicenter Study of Perioperative Ischemia Research Group. Aspirin and mortality from coronary bypass surgery. N Engl J Med 2002; 347:1309.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dacey LJ, Munoz JJ, Johnson ER, et al. Effect of preoperative aspirin use on mortality in coronary artery bypass grafting patients. Ann Thorac Surg 2000; 70:1986.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Devereaux PJ, Mrkobrada M, Sessler DI, et al. Aspirin in patients undergoing noncardiac surgery. N Engl J Med 2014; 370:1494.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Eikelboom JW, Kearon C, Guyatt G, et al. Perioperative Aspirin for Prevention of Venous Thromboembolism: The PeriOperative ISchemia Evaluation-2 Trial and a Pooled Analysis of the Randomized Trials. Anesthesiology 2016; 125:1121.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Narouze S, Benzon HT, Provenzano D, et al. Interventional Spine and Pain Procedures in Patients on Antiplatelet and Anticoagulant Medications (Second Edition): Guidelines From the American Society of Regional Anesthesia and Pain Medicine, the European Society of Regional Anaesthesia and Pain Therapy, the American Academy of Pain Medicine, the International Neuromodulation Society, the North American Neuromodulation Society, and the World Institute of Pain. Reg Anesth Pain Med 2018; 43:225.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Diener HC, Cunha L, Forbes C, et al. European Stroke Prevention Study. 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci 1996; 143:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Beattie WS, Warriner CB, Etches R, et al. The addition of continuous intravenous infusion of ketorolac to a patient-controlled analgetic morphine regime reduced postoperative myocardial ischemia in patients undergoing elective total hip or knee arthroplasty. Anesth Analg 1997; 84:715.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Teerawattananon C, Tantayakom P, Suwanawiboon B, Katchamart W. Risk of perioperative bleeding related to highly selective cyclooxygenase-2 inhibitors: A systematic review and meta-analysis. Semin Arthritis Rheum 2017; 46:520.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Warth LC, Noiseux NO, Hogue MH, et al. Risk of Acute Kidney Injury After Primary and Revision Total Hip Arthroplasty and Total Knee Arthroplasty Using a Multimodal Approach to Perioperative Pain Control Including Ketorolac and Celecoxib. J Arthroplasty 2016; 31:253.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Douketis JD, Berger PB, Dunn AS, et al. The perioperative management of antithrombotic therapy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133:299S.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Van Hecken A, Schwartz JI, Depré M, et al. Comparative inhibitory activity of rofecoxib, meloxicam, diclofenac, ibuprofen, and naproxen on COX-2 versus COX-1 in healthy volunteers. J Clin Pharmacol 2000; 40:1109.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nunn B, Chamberlain PD. Effect of nabumetone (BRL 14777), a new anti-inflammatory drug, on human platelet reactivity ex vivo: comparison with naproxen. J Pharm Pharmacol 1982; 34:576.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Goldenberg NA, Jacobson L, Manco-Johnson MJ. Brief communication: duration of platelet dysfunction after a 7-day course of Ibuprofen. Ann Intern Med 2005; 142:506.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cronberg S, Wallmark E, Söderberg I. Effect on platelet aggregation of oral administration of 10 non-steroidal analgesics to humans. Scand J Haematol 1984; 33:155.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Borthwick E, Ferguson A. Perioperative acute kidney injury: risk factors, recognition, management, and outcomes. BMJ 2010; 341:c3365.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Huyse FJ, Touw DJ, van Schijndel RS, et al. Psychotropic drugs and the perioperative period: a proposal for a guideline in elective surgery. Psychosomatics 2006; 47:8.
          </a>
         </li>
         <li class="breakAll">
          Depaulo JR, Barker LR. Affective disorders. In: Principles of Ambulatory Medicine, Barker LR, Burton JR, Zieve PD (Eds), Williams and Wilkins, Baltimore 1995. p.166.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Labos C, Dasgupta K, Nedjar H, et al. Risk of bleeding associated with combined use of selective serotonin reuptake inhibitors and antiplatelet therapy following acute myocardial infarction. CMAJ 2011; 183:1835.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ziegelstein RC, Meuchel J, Kim TJ, et al. Selective serotonin reuptake inhibitor use by patients with acute coronary syndromes. Am J Med 2007; 120:525.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yuan Y, Tsoi K, Hunt RH. Selective serotonin reuptake inhibitors and risk of upper GI bleeding: confusion or confounding? Am J Med 2006; 119:719.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Auerbach AD, Vittinghoff E, Maselli J, et al. Perioperative use of selective serotonin reuptake inhibitors and risks for adverse outcomes of surgery. JAMA Intern Med 2013; 173:1075.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sajan F, Conte JV, Tamargo RJ, et al. Association of Selective Serotonin Reuptake Inhibitors with Transfusion in Surgical Patients. Anesth Analg 2016; 123:21.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           van Haelst IM, Egberts TC, Doodeman HJ, et al. Use of serotonergic antidepressants and bleeding risk in orthopedic patients. Anesthesiology 2010; 112:631.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tavakoli HR, DeMaio M, Wingert NC, et al. Serotonin reuptake inhibitors and bleeding risks in major orthopedic procedures. Psychosomatics 2012; 53:559.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Andreasen JJ, Riis A, Hjortdal VE, et al. Effect of selective serotonin reuptake inhibitors on requirement for allogeneic red blood cell transfusion following coronary artery bypass surgery. Am J Cardiovasc Drugs 2006; 6:243.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tully PJ, Cardinal T, Bennetts JS, Baker RA. Selective serotonin reuptake inhibitors, venlafaxine and duloxetine are associated with in hospital morbidity but not bleeding or late mortality after coronary artery bypass graft surgery. Heart Lung Circ 2012; 21:206.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Xiong GL, Jiang W, Clare RM, et al. Safety of selective serotonin reuptake inhibitor use prior to coronary artery bypass grafting. Clin Cardiol 2010; 33:E94.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kim DH, Daskalakis C, Whellan DJ, et al. Safety of selective serotonin reuptake inhibitor in adults undergoing coronary artery bypass grafting. Am J Cardiol 2009; 103:1391.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Singh I, Achuthan S, Chakrabarti A, et al. Influence of pre-operative use of serotonergic antidepressants (SADs) on the risk of bleeding in patients undergoing different surgical interventions: a meta-analysis. Pharmacoepidemiol Drug Saf 2015; 24:237.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mason PJ, Morris VA, Balcezak TJ. Serotonin syndrome. Presentation of 2 cases and review of the literature. Medicine (Baltimore) 2000; 79:201.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stack CG, Rogers P, Linter SP. Monoamine oxidase inhibitors and anaesthesia. A review. Br J Anaesth 1988; 60:222.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ray WA, Chung CP, Murray KT, et al. Atypical antipsychotic drugs and the risk of sudden cardiac death. N Engl J Med 2009; 360:225.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Larsen KA, Kelly SE, Stern TA, et al. Administration of olanzapine to prevent postoperative delirium in elderly joint-replacement patients: a randomized, controlled trial. Psychosomatics 2010; 51:409.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wang W, Li HL, Wang DX, et al. Haloperidol prophylaxis decreases delirium incidence in elderly patients after noncardiac surgery: a randomized controlled trial*. Crit Care Med 2012; 40:731.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Levenson JL. High-dose intravenous haloperidol for agitated delirium following lung transplantation. Psychosomatics 1995; 36:66.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tesar GE, Stern TA. Evaluation and treatment of agitation in the intensive care unit. Intensive Care Med 1986; 1:137.
          </a>
         </li>
         <li class="breakAll">
          Wise MG, Terrell CD. Neuropsychiatric disorders; delirium, psychotic disorders, and anxiety. In: Principles of Critical Care, 2nd ed, Hall JB, Schmidt GA, Wood LD (Eds), McGraw-Hill, New York 1998. p.965.
         </li>
         <li class="breakAll">
          Pozuelo L, et al. Preoperative Psychiatric Evaluation and Perioperative Management of Patients with Psychiatric Disorders. In: Comprehensive Hospital Medicine: An Evidence-Based Approach, Williams MV (Ed), Saunders, Philadelphia 2007.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ward N, Roth JS, Lester CC, et al. Anxiolytic medication is an independent risk factor for 30-day morbidity or mortality after surgery. Surgery 2015; 158:420.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lenhardt R, Orhan-Sungur M, Komatsu R, et al. Suppression of shivering during hypothermia using a novel drug combination in healthy volunteers. Anesthesiology 2009; 111:110.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fischer SP, Schmiesing CA, Guta CG, Brock-Utne JG. General anesthesia and chronic amphetamine use: should the drug be stopped preoperatively? Anesth Analg 2006; 103:203.
          </a>
         </li>
         <li class="breakAll">
          Pharmacology of Opiod Analgesics. In: Anesthesiology, Longnecker DE (Ed), McGraw-Hill, New York 2012.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Huxtable CA, Roberts LJ, Somogyi AA, MacIntyre PE. Acute pain management in opioid-tolerant patients: a growing challenge. Anaesth Intensive Care 2011; 39:804.
          </a>
         </li>
         <li class="breakAll">
          Kelly WN, Fox IH, Palelleo TD. Gout and related disorders of purine metabolism. In: Textbook of Rheumatology, WB Saunders, Philadelphia 1989. p.1395.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wilbur K, Makowsky M. Colchicine myotoxicity: case reports and literature review. Pharmacotherapy 2004; 24:1784.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wallace SL, Singer JZ. Review: systemic toxicity associated with the intravenous administration of colchicine--guidelines for use. J Rheumatol 1988; 15:495.
          </a>
         </li>
         <li class="breakAll">
          www.fda.gov/medwatch/safety/2005/safety05.htm#Flomax (Accessed on February 22, 2008).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chang DF, Campbell JR. Intraoperative floppy iris syndrome associated with tamsulosin. J Cataract Refract Surg 2005; 31:664.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schwinn DA, Afshari NA. Alpha1-adrenergic antagonists and floppy iris syndrome: tip of the iceberg? Ophthalmology 2005; 112:2059.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kaye AD, Clarke RC, Sabar R, et al. Herbal medicines: current trends in anesthesiology practice--a hospital survey. J Clin Anesth 2000; 12:468.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ang-Lee MK, Moss J, Yuan CS. Herbal medicines and perioperative care. JAMA 2001; 286:208.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 4814 Version 87.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10759691" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Polypharmacy in a general surgical unit and consequences of drug withdrawal.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9563428" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Chronic medications in the perioperative period.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11565489" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Stopping and restarting medications in the perioperative period.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8808166" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Perioperative management of drug therapy, clinical considerations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19084896" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Results of a medication reconciliation survey from the 2006 Society of Hospital Medicine national meeting.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15156966" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Discontinuation and reinstitution of medications during the perioperative period.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37094336" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Hypotension-Avoidance Versus Hypertension-Avoidance Strategies in Noncardiac Surgery : An International Randomized Controlled Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11136500" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Perioperative beta-blocker withdrawal and mortality in vascular surgical patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20864832" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Association of the pattern of use of perioperativeβ-blockade and postoperative mortality.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29200062" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Is Compliance With Surgical Care Improvement Project Cardiac (SCIP-Card-2) Measures for Perioperativeβ-Blockers Associated With Reduced Incidence of Mortality and Cardiovascular-Related Critical Quality Indicators After Noncardiac Surgery?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19926021" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : 2009 ACCF/AHA focused update on perioperative beta blockade.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19926021" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : 2009 ACCF/AHA focused update on perioperative beta blockade.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6135253" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Myocardial protective effect of maintained beta-blockade in aorto-coronary bypass surgery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6130666" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : beta-Receptor blockade and neurolept anaesthesia. Withdrawal vs continuation of long-term therapy in gall-bladder and carotid artery surgery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23612244" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Perioperative metoprolol and risk of stroke after noncardiac surgery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23820187" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Selectiveβ1-antagonism with bisoprolol is associated with fewer postoperative strokes than atenolol or metoprolol: a single-center cohort study of 44,092 consecutive patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23588263" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Differentβ-blockers and initiation time in patients undergoing noncardiac surgery: a meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21372680" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Perioperativeβ-blockade: atenolol is associated with reduced mortality when compared to metoprolol.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20102888" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Impact of prophylactic beta-blocker therapy to prevent stroke after noncardiac surgery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8873539" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Small, oral dose of clonidine reduces the incidence of intraoperative myocardial ischemia in patients having vascular surgery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10519497" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Effect of mivazerol on perioperative cardiac complications during non-cardiac surgery in patients with coronary heart disease: the European Mivazerol Trial (EMIT).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15277909" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Effect of clonidine on cardiovascular morbidity and mortality after noncardiac surgery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24679061" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Clonidine in patients undergoing noncardiac surgery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24568963" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Aspirin and clonidine in non-cardiac surgery: acute kidney injury substudy protocol of the Perioperative Ischaemic Evaluation (POISE) 2 randomised controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6122433" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Withdrawal syndromes and the cessation of antihypertensive therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6114720" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Withdrawal syndromes and the cessation of antihypertensive therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/453602" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Preoperative clonidine withdrawal syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3026180" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Rebound hypertension after discontinuation of transdermal clonidine therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6115570" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Abrupt cessation of treatment in hypertension: consideration of clinical features, mechanisms, prevention and management of the discontinuation syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/422739" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Withdrawal syndrome following cessation of guanabenz therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1498296" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Hemodynamic effect of calcium channel blockade during anesthesia for coronary artery surgery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15001904" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Calcium antagonists are associated with reduced mortality after cardiac surgery: a propensity analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12933374" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Calcium channel blockers for reducing cardiac morbidity after noncardiac surgery: a meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6756213" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Calcium entry blockers: uses and implications for anesthesiologists.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6732337" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Rebound vasospasm after coronary revascularization in association with calcium antagonist withdrawal.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11343438" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Epidemiologic review of the calcium channel blocker drugs. An up-to-date perspective on the proposed hazards.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8614913" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Nimodipine neuroprotection in cardiac valve replacement: report of an early terminated trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7711582" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Surgical bleeding: unexpected effect of a calcium antagonist.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9066477" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Use of calcium antagonists and need for perioperative transfusion in older patients with hip fracture: observational study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9469785" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Effects of calcium antagonists on the risks of coronary heart disease, cancer and bleeding. Ad Hoc Subcommittee of the Liaison Committee of the World Health Organisation and the International Society of Hypertension.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Calcium antagonist use and perioperative bleeding complications: an analysis of 5,157 patients
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1485371" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Pharmacokinetics of diltiazem in patients undergoing coronary artery bypass grafting.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18375317" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Chronic angiotensin-converting enzyme inhibitor or angiotensin receptor blocker therapy combined with diuretic therapy is associated with increased episodes of hypotension in noncardiac surgery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22253266" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Angiotensin converting enzyme inhibitors are not associated with respiratory complications or mortality after noncardiac surgery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30261084" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Prospective Randomized Evaluation of Preoperative Angiotensin-Converting Enzyme Inhibition (PREOP-ACEI).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29381513" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : A Systematic Review of Outcomes Associated With Withholding or Continuing Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers Before Noncardiac Surgery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27775997" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Withholding versus Continuing Angiotensin-converting Enzyme Inhibitors or Angiotensin II Receptor Blockers before Noncardiac Surgery: An Analysis of the Vascular events In noncardiac Surgery patIents cOhort evaluatioN Prospective Cohort.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37935833" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Discontinuation vs. continuation of renin-angiotensin system inhibition before non-cardiac surgery: the SPACE trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10690132" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Effect of omitting regular ACE inhibitor medication before cardiac surgery on haemodynamic variables and vasoactive drug requirements.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19875309" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Prophylactic vasopressin in patients receiving the angiotensin-converting enzyme inhibitor ramipril undergoing coronary artery bypass graft surgery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22715473" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Patterns of use of perioperative angiotensin-converting enzyme inhibitors in coronary artery bypass graft surgery with cardiopulmonary bypass: effects on in-hospital morbidity and mortality.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18852580" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Preoperative angiotensin-converting enzyme inhibitors protect myocardium from ischemia during coronary artery bypass graft surgery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18805152" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Preoperative Angiotensin-converting enzyme inhibitors and acute kidney injury after coronary artery bypass grafting.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18667735" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Preoperative use of angiotensin-converting enzyme inhibitors/angiotensin receptor blockers is associated with increased risk for acute kidney injury after cardiovascular surgery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25800881" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Preoperative renin-angiotensin system inhibitors use linked to reduced acute kidney injury: a systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24694072" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Association between angiotensin converting enzyme inhibitor or angiotensin receptor blocker use prior to major elective surgery and the risk of acute dialysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24464761" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Angiotensin axis blockade, hypotension, and acute kidney injury in elective major orthopedic surgery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26200181" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Association between Withholding Angiotensin Receptor Blockers in the Early Postoperative Period and 30-day Mortality: A Cohort Study of the Veterans Affairs Healthcare System.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24799360" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Thirty-day mortality risk associated with the postoperative nonresumption of angiotensin-converting enzyme inhibitors: a retrospective study of the Veterans Affairs Healthcare System.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25085961" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : 2014 ACC/AHA guideline on perioperative cardiovascular evaluation and management of patients undergoing noncardiac surgery: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25086026" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : 2014 ESC/ESA Guidelines on non-cardiac surgery: cardiovascular assessment and management: The Joint Task Force on non-cardiac surgery: cardiovascular assessment and management of the European Society of Cardiology (ESC) and the European Society of Anaesthesiology (ESA).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27865641" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Canadian Cardiovascular Society Guidelines on Perioperative Cardiac Risk Assessment and Management for Patients Who Undergo Noncardiac Surgery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3341565" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : The overstated risk of preoperative hypokalemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8775868" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Supraventricular tachycardia after coronary artery bypass grafting surgery and fluid and electrolyte variables.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21035594" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Risk of intraoperative hypotension with loop diuretics: a randomized controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21035594" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Risk of intraoperative hypotension with loop diuretics: a randomized controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21035594" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Risk of intraoperative hypotension with loop diuretics: a randomized controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21035594" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Risk of intraoperative hypotension with loop diuretics: a randomized controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11758079" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Statin-associated myopathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11485144" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Statin-fibrate combination therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1535109" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Predictors of postoperative myocardial ischemia in patients undergoing noncardiac surgery. The Study of Perioperative Ischemia Research Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9729180" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Supraventricular arrhythmia in patients having noncardiac surgery: clinical correlates and effect on length of stay.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10702463" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : A comparison of rabeprazole, lansoprazole, and ranitidine for improving preoperative gastric fluid property in adults undergoing elective surgery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2605070" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : Effect of i.v. omeprazole on the pH and volume of gastric contents before surgery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1674198" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Central nervous system reactions to histamine-2 receptor blockers.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15603206" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : Low incidence of complications in asthmatic patients treated with preoperative corticosteroids.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9625400" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : Montelukast, a once-daily leukotriene receptor antagonist, in the treatment of chronic asthma: a multicenter, randomized, double-blind trial. Montelukast Clinical Research Study Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9625400" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : Montelukast, a once-daily leukotriene receptor antagonist, in the treatment of chronic asthma: a multicenter, randomized, double-blind trial. Montelukast Clinical Research Study Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2073759" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : Oral contraceptive therapy and the surgical management of ENT patients: a review of current clinical practice.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11357157" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : Oral contraceptives and the risk of venous thrombosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10787361" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : Postmenopausal hormone therapy increases risk for venous thromboembolic disease. The Heart and Estrogen/progestin Replacement Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11992304" id="rid81" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          82 : Postmenopausal estrogen replacement and risk for venous thromboembolism: a systematic review and meta-analysis for the U.S. Preventive Services Task Force.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15269830" id="rid82" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          83 : Postmenopausal hormone replacement and venous thromboembolism following hip and knee arthroplasty.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17309934" id="rid83" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          84 : Hormone therapy and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration and progestogens: the ESTHER study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20230416" id="rid84" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          85 : Hormone replacement therapy and the risk of venous thromboembolism: a population-based study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19834106" id="rid85" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          86 : Postmenopausal hormone therapy and risk of idiopathic venous thromboembolism: results from the E3N cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10376571" id="rid86" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          87 : The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9747868" id="rid87" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          88 : Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9747868" id="rid88" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          89 : Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1929684" id="rid89" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          90 : Should nonsteroidal anti-inflammatory drugs be stopped before elective surgery?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2404046" id="rid90" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          91 : Implications of preoperative administration of aspirin in patients undergoing coronary artery bypass grafting. Department of Veterans Affairs Cooperative Study on Antiplatelet Therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1985613" id="rid91" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          92 : Preoperative aspirin therapy and reoperation for bleeding after coronary artery bypass surgery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8540646" id="rid92" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          93 : Unplanned reoperation for bleeding.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2393802" id="rid93" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          94 : Identifiable factors in post-prostatectomy haemorrhage: the role of aspirin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2400264" id="rid94" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          95 : Low-dose preoperative aspirin therapy, postoperative blood loss, and transfusion requirements.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12397188" id="rid95" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          96 : Aspirin and mortality from coronary bypass surgery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11156107" id="rid96" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          97 : Effect of preoperative aspirin use on mortality in coronary artery bypass grafting patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24679062" id="rid97" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          98 : Aspirin in patients undergoing noncardiac surgery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27627817" id="rid98" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          99 : Perioperative Aspirin for Prevention of Venous Thromboembolism: The PeriOperative ISchemia Evaluation-2 Trial and a Pooled Analysis of the Randomized Trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29278603" id="rid99" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          100 : Interventional Spine and Pain Procedures in Patients on Antiplatelet and Anticoagulant Medications (Second Edition): Guidelines From the American Society of Regional Anesthesia and Pain Medicine, the European Society of Regional Anaesthesia and Pain Therapy, the American Academy of Pain Medicine, the International Neuromodulation Society, the North American Neuromodulation Society, and the World Institute of Pain.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8981292" id="rid100" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          101 : European Stroke Prevention Study. 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9085945" id="rid101" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          102 : The addition of continuous intravenous infusion of ketorolac to a patient-controlled analgetic morphine regime reduced postoperative myocardial ischemia in patients undergoing elective total hip or knee arthroplasty.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27569276" id="rid102" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          103 : Risk of perioperative bleeding related to highly selective cyclooxygenase-2 inhibitors: A systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26377377" id="rid103" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          104 : Risk of Acute Kidney Injury After Primary and Revision Total Hip Arthroplasty and Total Knee Arthroplasty Using a Multimodal Approach to Perioperative Pain Control Including Ketorolac and Celecoxib.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18574269" id="rid104" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          105 : The perioperative management of antithrombotic therapy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11028250" id="rid105" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          106 : Comparative inhibitory activity of rofecoxib, meloxicam, diclofenac, ibuprofen, and naproxen on COX-2 versus COX-1 in healthy volunteers.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6127382" id="rid106" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          107 : Effect of nabumetone (BRL 14777), a new anti-inflammatory drug, on human platelet reactivity ex vivo: comparison with naproxen.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15809462" id="rid107" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          108 : Brief communication: duration of platelet dysfunction after a 7-day course of Ibuprofen.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6474093" id="rid108" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          109 : Effect on platelet aggregation of oral administration of 10 non-steroidal analgesics to humans.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20603317" id="rid109" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          110 : Perioperative acute kidney injury: risk factors, recognition, management, and outcomes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16384803" id="rid110" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          111 : Psychotropic drugs and the perioperative period: a proposal for a guideline in elective surgery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16384803" id="rid111" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          112 : Psychotropic drugs and the perioperative period: a proposal for a guideline in elective surgery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21948719" id="rid112" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          113 : Risk of bleeding associated with combined use of selective serotonin reuptake inhibitors and antiplatelet therapy following acute myocardial infarction.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17524755" id="rid113" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          114 : Selective serotonin reuptake inhibitor use by patients with acute coronary syndromes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16945603" id="rid114" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          115 : Selective serotonin reuptake inhibitors and risk of upper GI bleeding: confusion or confounding?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23699725" id="rid115" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          116 : Perioperative use of selective serotonin reuptake inhibitors and risks for adverse outcomes of surgery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27159071" id="rid116" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          117 : Association of Selective Serotonin Reuptake Inhibitors with Transfusion in Surgical Patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20179499" id="rid117" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          118 : Use of serotonergic antidepressants and bleeding risk in orthopedic patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23157994" id="rid118" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          119 : Serotonin reuptake inhibitors and bleeding risks in major orthopedic procedures.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16913825" id="rid119" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          120 : Effect of selective serotonin reuptake inhibitors on requirement for allogeneic red blood cell transfusion following coronary artery bypass surgery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22285303" id="rid120" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          121 : Selective serotonin reuptake inhibitors, venlafaxine and duloxetine are associated with in hospital morbidity but not bleeding or late mortality after coronary artery bypass graft surgery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20552618" id="rid121" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          122 : Safety of selective serotonin reuptake inhibitor use prior to coronary artery bypass grafting.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19427434" id="rid122" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          123 : Safety of selective serotonin reuptake inhibitor in adults undergoing coronary artery bypass grafting.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24789076" id="rid123" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          124 : Influence of pre-operative use of serotonergic antidepressants (SADs) on the risk of bleeding in patients undergoing different surgical interventions: a meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10941349" id="rid124" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          125 : Serotonin syndrome. Presentation of 2 cases and review of the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3278728" id="rid125" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          126 : Monoamine oxidase inhibitors and anaesthesia. A review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19144938" id="rid126" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          127 : Atypical antipsychotic drugs and the risk of sudden cardiac death.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20833940" id="rid127" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          128 : Administration of olanzapine to prevent postoperative delirium in elderly joint-replacement patients: a randomized, controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22067628" id="rid128" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          129 : Haloperidol prophylaxis decreases delirium incidence in elderly patients after noncardiac surgery: a randomized controlled trial*.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7871137" id="rid129" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          130 : High-dose intravenous haloperidol for agitated delirium following lung transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid130" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          131 : Evaluation and treatment of agitation in the intensive care unit
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid131" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          132 : Evaluation and treatment of agitation in the intensive care unit
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid132" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          133 : Evaluation and treatment of agitation in the intensive care unit
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26032825" id="rid133" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          134 : Anxiolytic medication is an independent risk factor for 30-day morbidity or mortality after surgery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19512867" id="rid134" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          135 : Suppression of shivering during hypothermia using a novel drug combination in healthy volunteers.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16790654" id="rid135" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          136 : General anesthesia and chronic amphetamine use: should the drug be stopped preoperatively?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16790654" id="rid136" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          137 : General anesthesia and chronic amphetamine use: should the drug be stopped preoperatively?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21970125" id="rid137" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          138 : Acute pain management in opioid-tolerant patients: a growing challenge.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21970125" id="rid138" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          139 : Acute pain management in opioid-tolerant patients: a growing challenge.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15585444" id="rid139" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          140 : Colchicine myotoxicity: case reports and literature review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3288754" id="rid140" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          141 : Review: systemic toxicity associated with the intravenous administration of colchicine--guidelines for use.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3288754" id="rid141" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          142 : Review: systemic toxicity associated with the intravenous administration of colchicine--guidelines for use.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15899440" id="rid142" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          143 : Intraoperative floppy iris syndrome associated with tamsulosin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16325704" id="rid143" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          144 : Alpha1-adrenergic antagonists and floppy iris syndrome: tip of the iceberg?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11090733" id="rid144" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          145 : Herbal medicines: current trends in anesthesiology practice--a hospital survey.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11448284" id="rid145" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          146 : Herbal medicines and perioperative care.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
